Colgate-Palmolive (CL) 10-K 17 Feb 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Jan. 31, 2022	Jun. 30, 2021
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-644
Entity Registrant Name	COLGATE-PALMOLIVE COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-1815595
Entity Address, Address Line One	300 Park Avenue
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	212
Local Phone Number	310-2000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 68.6
Entity Common Stock, Shares Outstanding		840,487,222
Documents Incorporated by Reference	Documents Form 10-K Reference Portions of Proxy Statement for the 2022 Annual Meeting of Stockholders Part III, Items 10 through 14
Entity Central Index Key	0000021665
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	CL
Security Exchange Name	NYSE
0.500% Notes Due 2026
Entity Information [Line Items]
Title of 12(b) Security	0.500% Notes due 2026
Trading Symbol	CL26
Security Exchange Name	NYSE
0.000% Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	0.300% Notes due 2029
Trading Symbol	CL29
Security Exchange Name	NYSE
1.375% Notes Due 2034
Entity Information [Line Items]
Title of 12(b) Security	1.375% Notes due 2034
Trading Symbol	CL34
Security Exchange Name	NYSE
0.875% Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	0.875% Notes due 2039
Trading Symbol	CL39
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	New York, New York
Auditor Firm ID	238

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net sales	$ 17,421	$ 16,471	$ 15,693
Cost of sales	7,046	6,454	6,368
Gross profit	10,375	10,017	9,325
Selling, general and administrative expenses	6,407	6,019	5,575
Other (income) expense, net	65	113	196
Goodwill and indefinite-lived intangible impairment charges	571	0	0
Operating profit	3,332	3,885	3,554
Non-service related postretirement costs	70	74	108
Interest (income) expense, net	175	164	145
Income before income taxes	3,087	3,647	3,301
Provision for income taxes	749	787	774
Net income including noncontrolling interests	2,338	2,860	2,527
Less: Net income attributable to noncontrolling interests	172	165	160
Net income attributable to Colgate-Palmolive Company	$ 2,166	$ 2,695	$ 2,367
Earnings per common share, basic (in dollars per share)	$ 2.56	$ 3.15	$ 2.76
Earnings per common share, diluted (in dollars per share)	$ 2.55	$ 3.14	$ 2.75

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income including noncontrolling interests	$ 2,338	$ 2,860	$ 2,527
Other comprehensive income (loss), net of tax:
Cumulative translation adjustments	(193)	(24)	25
Retirement plan and other retiree benefit adjustments	134	(40)	(100)
Gains (losses) on cash flow hedges	16	(2)	(12)
Total Other comprehensive income (loss), net of tax	(43)	(66)	(87)
Total Comprehensive income including noncontrolling interests	2,295	2,794	2,440
Less: Net income attributable to noncontrolling interests	172	165	160
Less: Cumulative translation adjustments attributable to noncontrolling interests	(2)	6	(2)
Total Comprehensive income attributable to noncontrolling interests	170	171	158
Total Comprehensive income attributable to Colgate-Palmolive Company	$ 2,125	$ 2,623	$ 2,282

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 832	$ 888
Receivables (net of allowances of $78 and $89, respectively)	1,297	1,264
Inventories	1,692	1,673
Other current assets	576	513
Total current assets	4,397	4,338
Property, plant and equipment, net	3,730	3,716
Goodwill	3,284	3,824
Other intangible assets, net	2,462	2,894
Deferred income taxes	193	291
Other assets	974	857
Total assets	15,040	15,920
Current Liabilities
Notes and loans payable	39	258
Current portion of long-term debt	12	9
Accounts payable	1,479	1,393
Accrued income taxes	436	403
Other accruals	2,085	2,341
Total current liabilities	4,051	4,404
Long-term debt	7,194	7,334
Deferred income taxes	395	426
Other liabilities	2,429	2,655
Total liabilities	14,069	14,819
Commitments and contingent liabilities	0	0
Shareholders’ Equity
Common stock, $1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued)	1,466	1,466
Additional paid-in capital	3,269	2,969
Retained earnings	24,350	23,699
Accumulated other comprehensive income (loss)	(4,386)	(4,345)
Unearned compensation	(1)	(1)
Treasury stock, at cost	(24,089)	(23,045)
Total Colgate-Palmolive Company shareholders’ equity	609	743
Noncontrolling interests	362	358
Total equity	971	1,101
Total liabilities and equity	$ 15,040	$ 15,920

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Allowance for doubtful accounts receivable, current	$ 78	$ 89
Shareholders’ Equity
Common stock par value (in USD per share)	$ 1	$ 1
Common stock authorized (in shares)	2,000,000,000	2,000,000,000
Common stock issued (in shares)	1,465,706,360	1,465,706,360

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Millions		Total	Common Stock	Additional Paid-In Capital	Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Beginning balance at Dec. 31, 2018			$ 1,466	$ 2,204	$ (3)	$ (21,196)	$ 21,615	$ (4,188)	$ 299
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		$ 2,527					2,367		160
Other comprehensive income (loss), net of tax		(87)						(85)	(2)
Dividends	[1]						(1,472)		(141)
Stock-based compensation expense				100
Shares issued for stock options				210		305
Shares issued for restricted stock awards				(29)		29
Noncontrolling interests acquired									125
Treasury stock acquired						(1,202)
Other				3	1	1	(9)
Ending balance at Dec. 31, 2019			1,466	2,488	(2)	(22,063)	22,501	(4,273)	441
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		2,860					2,695		165
Other comprehensive income (loss), net of tax		(66)						(72)	6
Dividends	[1]						(1,502)		(152)
Stock-based compensation expense				107
Shares issued for stock options				400		462
Shares issued for restricted stock awards				(31)		31
Noncontrolling interests acquired									(99)
Treasury stock acquired						(1,476)
Other				5	1	1	5		(3)
Ending balance at Dec. 31, 2020		1,101	1,466	2,969	(1)	(23,045)	23,699	(4,345)	358
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		2,338					2,166		172
Other comprehensive income (loss), net of tax		(43)						(41)	(2)
Dividends	[1]						(1,515)		(166)
Stock-based compensation expense				135
Shares issued for stock options				188		248
Shares issued for restricted stock awards				(27)		27
Treasury stock acquired						(1,320)
Other				4	0	1	0		0
Ending balance at Dec. 31, 2021		$ 971	$ 1,466	$ 3,269	$ (1)	$ (24,089)	$ 24,350	$ (4,386)	$ 362
[1]	* Two dividends were declared in each of the first quarters of 2021, 2020 and 2019.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)	3 Months Ended			12 Months Ended
	Mar. 31, 2021Dividend	Mar. 31, 2020Dividend	Mar. 31, 2019Dividend	Dec. 31, 2021$ / shares	Dec. 31, 2020$ / shares	[1]	Dec. 31, 2019$ / shares	[1]
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in USD per share) | $ / shares				$ 1.79	$ 1.75		$ 1.71
Number of dividends declared per quarter | Dividend	2	2	2
[1]	* Two dividends were declared in each of the first quarters of 2021, 2020 and 2019.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Activities
Net income including noncontrolling interests		$ 2,338	$ 2,860	$ 2,527
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations:
Depreciation and amortization		556	539	519
Restructuring and termination benefits, net of cash		(21)	(71)	18
Stock-based compensation expense		135	107	100
Goodwill and indefinite-lived intangible impairment charges		571	0	0
Loss on early extinguishment of debt		75	23	0
Deferred income taxes		(132)	(120)	17
Voluntary benefit plan contributions		0	0	(113)
Cash effects of changes in:
Receivables		(84)	138	19
Inventories		(72)	(251)	(77)
Accounts payable and other accruals		14	520	36
Other non-current assets and liabilities		(55)	(26)	87
Net cash provided by operations		3,325	3,719	3,133
Investing Activities
Capital expenditures		(567)	(410)	(335)
Purchases of marketable securities and investments		(141)	(143)	(184)
Proceeds from sale of marketable securities and investments		141	124	131
Payment for acquisitions, net of cash acquired		0	(353)	(1,711)
Other investing activities		(25)	3	0
Net cash used in investing activities		(592)	(779)	(2,099)
Financing Activities
Short-term borrowing (repayment) less than 90 days, net		(171)	488	296
Principal payments on debt	[1]	(703)	(1,085)	(1,441)
Proceeds from issuance of debt		699	0	2,578
Dividends paid		(1,679)	(1,654)	(1,614)
Purchases of treasury shares		(1,320)	(1,476)	(1,202)
Proceeds from exercise of stock options		424	874	498
Purchases of non-controlling interests in subsidiaries		0	(99)	0
Other financing activities		(24)	33	15
Net cash used in financing activities		(2,774)	(2,919)	(870)
Effect of exchange rate changes on Cash and cash equivalents		(15)	(16)	(7)
Net (decrease) increase in Cash and cash equivalents		(56)	5	157
Cash and cash equivalents at beginning of year		888	883	726
Cash and cash equivalents at end of year		832	888	883
Supplemental Cash Flow Information
Income taxes paid		890	845	803
Interest paid		$ 194	$ 188	$ 185
[1]	(1) For the years ended December 31, 2021 and 2020, Principal payments on debt includes cash charges of $75 and $20, respectively, related to the extinguishment of debt prior to maturity. See Note 6, Long-Term Debt and Credit Facilities for additional information.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Cash charges for extinguishment of debt prior to maturity	$ 75	$ 20

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations The Company manufactures and markets a wide variety of products in the U.S. and around the world in two product segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners and other similar items. These products are sold primarily to a variety of traditional and eCommerce retailers, wholesalers and distributors worldwide. Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill’s Pet Nutrition. The principal customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and eCommerce retailers. Some of our products are also sold direct-to-consumer. Principal global and regional trademarks include Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. The Company’s principal classes of products accounted for the following percentages of worldwide Net sales for the past three years: 2021 2020 2019 Oral Care 44 % 44 % 46 % Personal Care 20 % 21 % 20 % Home Care 17 % 18 % 18 % Pet Nutrition 19 % 17 % 16 % Total 100 % 100 % 100 %

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company’s investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2021 and 2020, equity method investments included in Other assets in the Consolidated Balance Sheets were $64 and $56, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company’s assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates. Revenue Recognition The Company’s revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to “direct the use of” and “obtain” the benefit from our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company’s right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers. Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company’s historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company’s promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates. Sales returns are generally accepted at the Company’s discretion and are not material to the Company’s Consolidated Financial Statements. The Company’s contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses. Shipping and Handling Costs Shipping and handling costs are classified as Selling, general and administrative expenses and were $1,687, $1,392 and $1,275 for the years ended December 31, 2021, 2020 and 2019, respectively. Marketing Costs The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Inventories The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of all other inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current “Other assets.” Property, Plant and Equipment Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over-estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses. Goodwill and Other Intangibles Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit. Income Taxes The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes. Financial Instruments Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 7, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations. Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton ( “ Black-Scholes ” ) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 8, Capital Stock and Stock-Based Compensation Plans. Currency Translation The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year. For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company. Recent Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, “Government Assistance (Topic 832).” This ASU requires increased disclosure on an annual basis about transactions with domestic, foreign, local, regional and national governments, including entities related to those governments and intergovernmental organizations, that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance. This guidance is effective for the Company beginning on January 1, 2022 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606).” This guidance is effective for the Company beginning on January 1, 2023 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In January 2021, the FASB issued ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope.” This ASU clarifies that certain optional expedients and exceptions in Topic 848 apply to derivatives that are affected by the discounting transition. This guidance was effective upon issuance for the Company and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, “Codification Improvements.” This ASU improves the consistency of the codification topics by including all disclosure guidance in the appropriate disclosure section and also clarifies the application of various provisions in the codification. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU provides optional expedients and exceptions for applying generally accepted accounting principles (“GAAP”) to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance was effective upon issuance of this ASU for contract modifications and hedging relationships on a prospective basis and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In January 2020, the FASB issued ASU No. 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, “Income taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance to improve consistent application. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements. Reclassifications

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Hello Products LLC (“hello”) On January 31, 2020, the Company acquired hello, an oral care business, for cash consideration of $351. The acquisition was financed with a combination of debt and cash. This acquisition is part of the Company’s strategy to focus on high growth segments within its Oral Care, Personal Care and Pet Nutrition businesses. The total purchase price consideration of $351 has been allocated to the net assets acquired based on their respective estimated fair values as follows: Receivables $ 11 Inventories 13 Other assets and liabilities, net (4) Other intangible assets 160 Goodwill 171 Fair value of net assets acquired $ 351 Other intangible assets acquired include trademarks, valued at $115, which are considered to have a finite useful life of 25 years, and customer relationships valued at $45, which are considered to have a finite useful life of 17 years. Goodwill of $171 was allocated to the North America segment and is deductible for tax purposes. Pro forma results of operations have not been presented as the impact on the Company’s Consolidated Financial Statements is not material.

Restructuring and Related Imple

Restructuring and Related Implementation Charges	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Related Implementation Charges	Restructuring and Related Implementation Charges 2022 Global Productivity Initiative On January 27, 2022, the Board approved a targeted productivity program (the “2022 Global Productivity Initiative”). The program is intended to reallocate resources towards the Company’s strategic priorities and faster growth businesses, drive efficiencies in the Company’s operations and streamline the Company’s supply chain to reduce structural costs. Implementation of the 2022 Global Productivity Initiative, which is expected to be substantially completed by December 31, 2022, is projected to result in cumulative pre-tax charges, once all phases are approved and implemented, totaling between $200 and $240, which are currently estimated to be comprised of the following: employee-related costs, including severance, pension and other termination benefits (80%); asset-related costs, primarily accelerated depreciation and asset write-downs (10%); and other charges (10%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. It is estimated that approximately 90% of the charges will result in cash expenditures. Global Growth and Efficiency Program The Global Growth and Efficiency Program, which commenced in the fourth quarter of 2012, concluded on December 31, 2019. Initiatives under the Global Growth and Efficiency Program fit within the program’s three focus areas of expanding commercial hubs, extending shared business services and streamlining global functions and optimizing the global supply chain and facilities. Substantially all initiatives under the Global Growth and Efficiency Program had been implemented as of December 31, 2019. In the third quarter of 2020, the Company adjusted the accrual balances related to certain projects approved prior to the conclusion of the Global Growth and Efficiency Program to reflect its revised estimate of remaining liabilities. This adjustment resulted in a reduction of $16 ($13 aftertax), of which a benefit of $3 was recorded in Selling, general and administrative expenses and $13 was recorded in Other (income) expense, net. For the year ended December 31, 2019, restructuring and related implementation charges are reflected in the Consolidated Statements of Income as follows: 2019 Cost of sales $ 8 Selling, general and administrative expenses 60 Other (income) expense, net 57 Non-service related postretirement costs 7 Total Global Growth and Efficiency Program charges, pretax $ 132 Total Global Growth and Efficiency Program charges, aftertax $ 102 Restructuring and related implementation charges in the preceding table and the adjustment recorded in the third quarter of 2020 were recorded in the Corporate segment as these initiatives were predominantly centrally directed and controlled and were not included in internal measures of segment operating performance. Total charges incurred for the Global Growth and Efficiency Program related to initiatives undertaken by the following reportable operating segments: Total Program 2019 Charges North America 4 % 17 % Latin America 12 % 5 % Europe 4 % 19 % Asia Pacific 6 % 4 % Africa/Eurasia (1) % 5 % Hill ’ s Pet Nutrition 2 % 8 % Corporate 73 % 42 % Total 100 % 100 % Over the course of the Global Growth and Efficiency Program, the Company incurred total pretax charges of $1,854 ($1,380 aftertax) in connection with the implementation of various projects as follows: Total Program Charges as of December 31, 2019 Employee-Related Costs $ 706 Incremental Depreciation 128 Asset Impairments 58 Other 962 Total $ 1,854 Over the course of the Global Growth and Efficiency Program, the majority of the costs incurred related to the following projects: the implementation of the Company’s overall hubbing strategy; the consolidation of facilities; the extension of shared business services and streamlining of global functions; the closing of the Morristown, New Jersey personal care facility; the simplification and streamlining of the Company’s research and development capabilities and oral care supply chain, both in Europe; redesigning the European commercial organization; restructuring how the Company will provide future retirement benefits to substantially all of the U.S.-based employees participating in the Company’s defined benefit retirement plan by shifting them to the Company’s defined contribution plan; and the implementation of a Corporate efficiencies program. Employee-Related Costs primarily included severance and other termination benefits and were calculated based on long-standing benefit practices, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also included pension and other retiree benefit enhancements. Incremental Depreciation was recorded to reflect changes in useful lives and estimated residual values for long-lived assets that will be taken out of service prior to the end of their normal service period. Asset Impairments were recorded to write down inventories and assets held for sale or disposal to their fair value based on amounts expected to be realized. Charges against assets within Asset Impairments are net of cash proceeds pertaining to the sale of certain assets.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The net carrying value of Goodwill as of December 31, 2021 and 2020 by segment was as follows: 2021 2020 Oral, Personal and Home Care North America $ 912 $ 912 Latin America 159 171 Europe 1,902 2,415 Asia Pacific 182 190 Africa/Eurasia 114 121 Total Oral, Personal and Home Care 3,269 3,809 Pet Nutrition 15 15 Total Goodwill $ 3,284 $ 3,824 The change in the amount of Goodwill during 2021 is due to the goodwill impairment charge related to the Filorga reporting unit as more fully described below, and foreign currency translation. Other intangible assets as of December 31, 2021 and 2020 were comprised of the following: 2021 2020 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trademarks - finite life $ 891 $ (445) $ 446 $ 902 $ (422) $ 480 Other finite life intangible assets 744 (289) 455 786 (237) 549 Indefinite life intangible assets 1,561 — 1,561 1,865 — 1,865 Total Other intangible assets $ 3,196 $ (734) $ 2,462 $ 3,553 $ (659) $ 2,894 The change in the net carrying amounts of Other intangible assets during 2021 was primarily due to the impact of impairment charge related to the Filorga indefinite-lived trademark as more fully described below, foreign currency translation and amortization expense of $89. Annual estimated amortization expense for each of the next five years is expected to be approximately $77. The Company made revisions to the internal forecasts relating to its Filorga reporting unit during the fourth quarter of 2021 due primarily to the impact of the COVID-19 pandemic on the Filorga skin health business as a result of government restrictions and reduced consumer mobility, which negatively impacted consumption in the duty-free, travel retail and pharmacy channels. The Company concluded that the changes in circumstances in this reporting unit triggered the need for an interim impairment review of its indefinite-lived trademark and goodwill and, accordingly, performed an interim impairment test for the trademark as of December 31, 2021. The Company concluded that the carrying value of the trademark exceeded its estimated fair value, and recorded an impairment charge of $204, reducing the carrying value to approximately $588. After adjusting the carrying value of the trademark, the Company completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $367 in the Filorga reporting unit, reducing the carrying value of goodwill to approximately $577. The goodwill and trademark impairment charges are presented as a separate line item in the Consolidated Statements of Income.

Long-Term Debt and Credit Facil

Long-Term Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt and Credit Facilities	Long-Term Debt and Credit Facilities Long-term debt consisted of the following at December 31: Weighted Average Interest Rate Maturities 2021 2020 Notes 1.9% 2022 - 2078 $ 5,958 $ 6,170 Commercial paper (0.4)% 2022 1,204 1,139 Finance Lease Obligations Various Various 44 34 7,206 7,343 Less: Current portion of long-term debt (12) (9) Total $ 7,194 $ 7,334 The weighted-average interest rate on short-term borrowings included in Notes and loans payable in the Consolidated Balance Sheets as of December 31, 2021 and 2020 was 0.7% and 4.8%, respectively. The Company classifies commercial paper and notes maturing within the next twelve months as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis. Excluding such obligations, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2021, were as follows: Years Ended December 31, 2022 $ 456 2023 908 2024 506 2025 135 2026 566 Thereafter 3,431 The Company has entered into interest rate swap agreements and foreign exchange contracts related to certain of these debt instruments. See Note 7, Fair Value Measurements and Financial Instruments for further information about the Company’s financial instruments. The Company’s debt issuances and redemptions support its capital structure strategy objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. During the fourth quarter of 2021, the Company issued €500 of eight-year notes at a fixed coupon rate of 0.300%. The debt issuance was under the Company’s shelf registration statement. An amount equal to the net proceeds of the notes will be used to finance or refinance, in part or in full, new and existing projects and programs with distinct environmental or social benefits. During the fourth quarter of 2021, the Company redeemed prior to maturity all of its outstanding 0.000% notes due 2021 with a principal amount of €500, originally issued on November 12, 2019. The redemption was financed with commercial paper borrowings. The redemption price was equal to the carrying amount of the debt extinguished. In 1990, the Company’s Canadian subsidiary (“CP Canada”), issued C$145 of Canadian dollar-denominated unsecured unsubordinated 12.85% guaranteed notes due October 4, 2030 (the “Canada notes”). During the third quarter of 2021, CP Canada redeemed the Canada notes and recorded a loss on the early extinguishment of debt of $75, which is included in Interest (income) expense, net in the Consolidated Statements of Income, representing the difference between the redemption price and the carrying amount of the debt extinguished. During the fourth quarter of 2020, the Company redeemed prior to maturity all of its outstanding 2.450% notes due 2021 with a principal amount $300, originally issued on November 8, 2011, and all of its outstanding 2.300% notes due 2022 with a principal amount of $500, originally issued on May 3, 2012. These redemptions were financed with commercial paper borrowings and cash. The Company recorded a loss on the early extinguishment of debt of $23, which is included in Interest (income) expense, net in the Consolidated Statements of Income, representing the difference between the redemption price and the carrying amount of the debt extinguished. At December 31, 2021, the Company had access to unused domestic and foreign lines of credit of $3,457 (including under the facility discussed below) and could also issue long-term debt pursuant to an effective shelf registration statement. In August 2021, the Company entered into a new $3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring August 2026, which replaced, on substantially similar terms, the Company’s $2,650 revolving credit facility that was scheduled to expire in November 2024. Commitment fees related to the credit facility are not material. The Company’s $1,500 364-day credit facility with a syndicate of banks expired in August 2021 and was not renewed. Certain agreements with respect to the Company’s bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote.

Fair Value Measurements and Fin

Fair Value Measurements and Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Company’s policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company’s treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. It is the Company’s policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged. Provided below are details of the Company’s exposures by type of risk and derivative instruments by type of hedge designation. Valuation Considerations The Company’s derivative instruments include interest rate swap contracts, forward-starting interest rate swaps, foreign currency contracts and commodity contracts. The Company utilizes interest rate swap contracts to manage its targeted mix of fixed and floating rate debt, and these swaps are classified as follows: Level 1: Based upon quoted market prices in active markets for identical assets or liabilities. Level 2: Based upon observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Based upon unobservable inputs reflecting the reporting entity’s own assumptions. Foreign Exchange Risk As the Company markets its products in over 200 countries and territories, it is exposed to currency fluctuations related to manufacturing and selling its products in currencies other than the U.S. dollar. The Company manages its foreign currency exposures through a combination of cost containment measures, sourcing strategies, selling price increases and the hedging of certain costs in an effort to minimize the impact on earnings of foreign currency rate movements. The Company primarily utilizes foreign currency contracts, including forward and swap contracts, option contracts, foreign and local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. The duration of foreign currency contracts generally does not exceed 12 months and the contracts are valued using observable market rates (Level 2 valuation). Interest Rate Risk The Company manages its targeted mix of fixed and floating rate debt with debt issuances and by entering into interest rate swaps in order to mitigate fluctuations in earnings and cash flows that may result from interest rate volatility. The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rate for future debt issuances. The notional amount, interest payment and maturity date of the swaps generally match the principal, interest payment and maturity date of the related debt, and the swaps are valued using observable benchmark rates (Level 2 valuation). Commodity Price Risk The Company is exposed to price volatility related to raw materials used in production, such as essential oils, resins, tropical oils, pulp, tallow, corn, poultry and soybeans. The Company manages its raw material exposures through a combination of cost containment measures, sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts. Futures contracts are used on a limited basis, primarily in the Hill’s Pet Nutrition segment, to manage volatility related to raw material inventory purchases of certain traded commodities, and these contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of the commodity contracts generally does not exceed 12 months. Credit Risk The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company’s policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020: Assets Liabilities Account Fair Value Account Fair Value Designated derivative instruments December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020 Interest rate swap contracts Other current assets $ 5 $ — Other accruals $ — $ — Interest rate swap contracts Other assets — 14 Other liabilities — — Forward-starting interest rate swaps Other assets 20 5 Other liabilities 21 — Foreign currency contracts Other current assets 22 7 Other accruals 6 93 Commodity contracts Other current assets 2 3 Other accruals — — Total designated $ 49 $ 29 $ 27 $ 93 Other financial instruments Marketable securities Other current assets 34 37 Total other financial instruments $ 34 $ 37 The carrying amount of cash, cash equivalents, accounts receivable and short-term debt approximated fair value as of December 31, 2021 and 2020. The estimated fair value of the Company’s long-term debt, including the current portion, as of December 31, 2021 and 2020, was $7,651 and $8,175, respectively, and the related carrying value was $7,206 and $7,343, respectively. The estimated fair value of long-term debt was derived principally from quoted prices on the Company’s outstanding fixed-term notes (Level 2 valuation). The following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges as of: December 31, 2021 December 31, 2020 Long-term debt: Carrying amount of hedged item $ 405 $ 413 Cumulative hedging adjustment included in the carrying amount $ 5 $ 14 The following tables present the notional values as of: December 31, 2021 Foreign Foreign Currency Debt Interest Rate Swaps Forward-Starting Interest Rate Swaps Commodity Contracts Fair Value Hedges $ 566 $ — $ 400 $ — $ — $ 966 Cash Flow Hedges 873 — — 700 24 1,597 Net Investment Hedges 173 4,600 — — — 4,773 December 31, 2020 Foreign Foreign Currency Debt Interest Rate Swaps Forward-Starting Interest Rate Swaps Commodity Contracts Fair Value Hedges $ 589 $ — $ 400 $ — $ — $ 989 Cash Flow Hedges 854 — — 300 17 1,171 Net Investment Hedges 528 4,523 — — — 5,051 The following table presents the location and amount of gains (losses) on hedges recognized on the Company’s Consolidated Statements of Income: Twelve Months Ended December 31, 2021 2020 Cost of sales Selling, general and administrative expenses Interest (income) expense, net Cost of sales Selling, general and administrative expenses Interest (income) expense, net Gain (loss) on hedges recognized in income: Interest rate swaps designated as fair value hedges: Derivative instrument $ — $ — $ 8 $ — $ — $ (10) Hedged items — — (8) — — 10 Foreign currency contracts designated as fair value hedges: Derivative instrument — 6 — — 29 — Hedged items — (6) — — (29) — Foreign currency contracts designated as cash flow hedges: Amount reclassified from OCI (12) — — 1 — — Commodity contracts designated as cash flow hedges: Amount reclassified from OCI 5 — — (1) — — Total gain (loss) on hedges recognized in income $ (7) $ — $ — $ — $ — $ — The following table presents the location and amount of unrealized gains (losses) on hedges included in OCI: Twelve Months Ended December 31, 2021 2020 Foreign currency contracts designated as cash flow hedges: Gain (loss) recognized in OCI $ 16 $ (11) Forward-starting interest rate swaps designated as cash flow hedges: Gain (loss) recognized in OCI (6) 5 Commodity contracts designated as cash flow hedges: Gain (loss) recognized in OCI 3 3 Foreign currency contracts designated as net investment hedges: Gain (loss) on instruments 30 (52) Gain (loss) on hedged items (30) 52 Foreign currency debt designated as net investment hedges: Gain (loss) on instruments 370 (356) Gain (loss) on hedged items (370) 356 Total unrealized gain (loss) on hedges recognized in OCI $ 13 $ (3)

Capital Stock and Stock-Based C

Capital Stock and Stock-Based Compensation Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Capital Stock and Stock-Based Compensation Plans	Capital Stock and Stock-Based Compensation Plans Preference Stock The Company has the authority to issue 50,262,150 shares of preference stock. Stock Repurchases On June 18, 2018, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to $5 billion under a new share repurchase program (the “2018 Program”), which replaced a previously authorized share repurchase program. The Company commenced repurchases of shares of the Company’s common stock under the 2018 Program beginning June 19, 2018. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors. The Company repurchased its common stock at a cost of $1,320 during 2021 under the 2018 Program. The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and the vesting of restricted stock unit awards. A summary of common stock and treasury stock activity for the three years ended December 31 is as follows: Common Stock Outstanding Treasury Stock Balance, January 1, 2019 862,912,792 602,793,568 Common stock acquired (17,219,642) 17,219,642 Shares issued for stock options 8,145,777 (8,145,777) Shares issued for restricted stock units and other 862,852 (862,852) Balance, December 31, 2019 854,701,779 611,004,581 Common stock acquired (18,701,843) 18,701,843 Shares issued for stock options 13,018,354 (13,018,354) Shares issued for restricted stock units and other 875,311 (875,311) Balance, December 31, 2020 849,893,601 615,812,759 Common stock acquired (16,518,163) 16,518,163 Shares issued for stock options 6,357,793 (6,357,793) Shares issued for restricted stock units and other 747,053 (747,053) Balance, December 31, 2021 840,480,284 625,226,076 Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units, based on the fair value of those awards at the date of grant. The fair value of restricted stock units, generally based on market prices, is amortized on a straight-line basis over the requisite service period. The estimated fair value of stock options on the date of grant is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award. Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation cost from the grant date through the date that the employee first becomes eligible to retire and is no longer required to provide service to earn the award. The Company has one incentive compensation plan pursuant to which it issues restricted stock units (both performance-based and time-vested) and stock options to employees and shares of common stock and stock options to non-employee directors. The Personnel and Organization Committee of the Board of Directors, which is comprised entirely of independent directors, administers the incentive compensation plan. The total stock-based compensation expense charged against pretax income for this plan was $135, $107 and $100 for the years ended December 31, 2021, 2020 and 2019, respectively. The total income tax benefit recognized on stock-based compensation, excluding excess tax benefits, was approximately $25, $20 and $20 for the years ended December 31, 2021, 2020 and 2019, respectively. Stock-based compensation expense is recorded within Selling, general and administrative expenses in the Corporate segment as these amounts are not included in internal measures of segment operating performance. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The weighted-average estimated fair value of stock options granted in the years ended December 31, 2021, 2020 and 2019 was $11.11, $11.26 and $10.48, respectively. Fair value is estimated using the Black-Scholes option pricing model with the assumptions summarized in the following table: 2021 2020 2019 Expected term of options 6 years 6 years 6 years Expected volatility rate 20.3 % 21.8 % 19.2 % Risk-free interest rate 1.0 % 0.5 % 1.5 % Expected dividend yield 2.3 % 2.3 % 2.3 % The weighted-average expected term of options granted each year was determined with reference to historical exercise and post-vesting cancellation experience, the vesting period of the awards and the contractual term of the awards, among other factors. Expected volatility incorporates implied share-price volatility derived from exchange traded options on the Company’s common stock. The risk-free interest rate for the expected term of the option is based on the yield of a zero-coupon U.S. Treasury bond with a maturity period equal to the option’s expected term. Performance-based Restricted Stock Units In 2019, the Company evolved its approach to granting long-term incentive compensation from granting time-vested restricted stock units following the conclusion of a three-year performance cycle to granting officers and other key employees a target number of unearned performance-based restricted stock units at the beginning of each three-year performance cycle. Awards are earned and vest following the conclusion of the performance period on the basis of achievement of performance goals established at the commencement of each three-year performance period. A summary of performance-based restricted stock unit activity for the year ended December 31, 2021 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Performance-based restricted stock units as of January 1, 2021 860 $ 73 Activity: Granted 355 70 Forfeited (189) 81 Performance-based restricted stock units as of December 31, 2021 1,026 $ 70 As of December 31, 2021, there was $26 of total unrecognized compensation expense related to unvested performance-based restricted stock unit awards, which will be recognized ratably over the remaining performance period. The Company uses a Monte-Carlo simulation model to estimate the fair value of performance-based restricted stock units at the date of grant. Time-Vested Restricted Stock Units The Company also grants time-vested restricted stock unit awards. As described above, under the Company’s previous long-term incentive program, time-vested restricted stock unit awards were granted to officers and other key employees following a three-year performance period. Awards vest at the end of the restriction period, which is three years from the date of grant. Awards for the 2018-2020 performance period were granted in 2021. No awards were granted in 2019 or 2020 for the 2016-2018 or 2017-2019 performance periods. As of December 31, 2021, approximately 10,990,000 shares of common stock were available for future restricted stock unit awards. A summary of restricted stock unit activity during 2021 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Restricted stock units as of January 1, 2021 1,897 $ 73 Activity: Granted 749 78 Vested (674) 70 Forfeited (56) 74 Restricted stock units as of December 31, 2021 1,916 $ 76 As of December 31, 2021, there was $56 of total unrecognized compensation expense related to unvested time-vested restricted stock unit awards, which will be recognized over a weighted-average period of 2 years. The total fair value of time-vested restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $47, $58 and $53, respectively. Stock Options The Company issues non-qualified stock options to non-employee directors, officers and other employees. Beginning in 2019, stock options have a contractual term of eight years. Prior to 2019, stock options generally had a contractual term of six years. Stock options generally vest ratably over three years. As of December 31, 2021, approximately 26,038,000 shares of common stock were available for future stock option grants. A summary of stock option activity during 2021 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Intrinsic Value of Unexercised Options outstanding, January 1, 2021 27,530 $ 71 Granted 5,120 77 Exercised (6,358) 68 Forfeited (173) 75 Expired (24) 73 Options outstanding, December 31, 2021 26,095 72 5 $ 309 Options exercisable, December 31, 2021 16,725 $ 72 3 $ 223 As of December 31, 2021, there was $32 of total unrecognized compensation expense related to unvested options, which will be recognized over a weighted-average period of 1.5 years. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $83, $136 and $84, respectively. The benefits of tax deductions in excess of grant date fair value resulting from the exercise of stock options and vesting of restricted stock unit awards for the years ended December 31, 2021, 2020 and 2019 were $9, $8 and $6, respectively, and are recognized in the provision for income taxes as a discrete item in the quarterly period in which they occur and classified as an operating cash flow. Cash proceeds received from options exercised for the years ended December 31, 2021, 2020 and 2019 were $424, $874 and $498, respectively.

Employee Stock Ownership Plan

Employee Stock Ownership Plan	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Employee Stock Ownership Plan	Employee Stock Ownership Plan In 1989, the Company expanded its Employee Stock Ownership Plan ( “ ESOP ” ) through the introduction of a leveraged ESOP that funds certain benefits for employees who have met eligibility requirements. As of December 31, 2021 and 2020, there were 10,290,667 and 11,545,950 shares of common stock, respectively, outstanding and issued to the Company ’ s ESOP. During 2000, the ESOP entered into a loan agreement with the Company under which the benefits of the ESOP may be extended through 2035. As of December 31, 2021, the ESOP had outstanding borrowings from the Company of $1, which represents unearned compensation shown as a reduction in Shareholders’ equity. Dividends on stock held by the ESOP are paid to the ESOP trust and, together with cash contributions from the Company, are (a) used by the ESOP to repay principal and interest, (b) credited to participant accounts, (c) used for contributions to the Company’s defined contribution plans or (d) used to pay the Company’s defined contribution plan expenses. Stock is allocated to participants based upon the ratio of the current year’s debt service to the sum of total outstanding principal and interest payments over the life of the debt. As of December 31, 2021, 9,559,255 shares of common stock had been released and allocated to participant accounts and 731,412 shares of common stock were available for future release and allocation to participant accounts. Dividends on the stock used to repay principal and interest or credited to participant accounts are deductible for income tax purposes and, accordingly, are reflected net of their tax benefit in the Consolidated Statements of Changes in Shareholders’ Equity. Annual expense related to the ESOP was $0 in 2021, 2020 and 2019. The Company paid dividends on the shares held by the ESOP of $20 in 2021, $23 in 2020 and $25 in 2019. The Company did not make any contributions to the ESOP in 2021, 2020 or 2019.

Retirement Plans and Other Reti

Retirement Plans and Other Retiree Benefits	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Retirement Plans and Other Retiree Benefits	Retirement Plans and Other Retiree Benefits Retirement Plans The Company and certain of its U.S. and foreign subsidiaries maintain defined benefit retirement plans. Benefits under these plans are based primarily on years of service and employees’ earnings. In the U.S., effective January 1, 2014, the Company provides virtually all future retirement benefits through the Company’s defined contribution plan. As a result, service after December 31, 2013 is not considered for participants in the Company’s principal U.S. defined benefit retirement plan. Participants in the Company’s principal U.S. defined benefit retirement plan whose retirement benefit was determined under the cash balance formula continue to earn interest credits on their vested balances as of December 31, 2013 but no longer receive pay credits. Participants whose retirement benefit was determined under the final average earnings formula or career average earnings formula continue to have their accrued benefit adjusted for pay increases until termination of employment. In the Company’s principal U.S. plans and certain funded foreign plans, funds are contributed to trusts in accordance with regulatory limits to provide for current service and for any unfunded projected benefit obligation over a reasonable period. The target asset allocation for the Company’s defined benefit plans is as follows: United States International Asset Category Equity securities 21 % 22 % Fixed income securities 76 % 63 % Real estate and other investments 3 % 15 % Total 100 % 100 % At December 31, 2021, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Other Retiree Cash and cash equivalents Level 1 $ 38 $ 9 $ — U.S. common stocks Level 1 — 2 — International common stocks Level 1 — 13 — Pooled funds (1) Level 1 48 116 — Fixed income securities (2) Level 2 905 67 — Guaranteed investment contracts (3) Level 2 1 51 — 992 258 — Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 361 97 — Fixed income funds (5) 469 328 — Hedge funds (6) — 8 — Multi-asset funds (7) 26 2 — Real estate funds (8) — 30 — 856 465 — Other assets and liabilities, net (9) (14) — — Total Investments $ 1,834 $ 723 $ — At December 31, 2020, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Other Retiree Cash and cash equivalents Level 1 $ 50 $ 12 $ — U.S. common stocks Level 1 — 1 — International common stocks Level 1 — 8 — Pooled funds (1) Level 1 65 117 — Fixed income securities (2) Level 2 1,117 59 2 Guaranteed investment contracts (3) Level 2 1 55 — 1,233 252 2 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 456 183 1 Fixed income funds (5) 136 225 — Hedge funds (6) — 6 — Multi-asset funds (7) 77 2 — Real estate funds (8) 34 30 — 703 446 1 Other assets and liabilities, net (9) (15) — — Total Investments $ 1,921 $ 698 $ 3 _______ (1) Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities. (2) The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2021, approximately 40% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds, compared to approximately 50% as of December 31, 2020. (3) The guaranteed investment contracts (“GICs”) represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption. (4) Investments that are measured at fair value using net asset value (“NAV”) per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly. (5) Fixed income funds primarily invest in U.S. government and investment grade corporate bonds. (6) Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options. (7) Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies. (8) Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager. (9) This category primarily includes unsettled trades for investments purchased and sold and dividend receivables. Equity securities in the U.S. plans did not include any investment in the Company’s common stock at either December 31, 2021 or December 31, 2020. In 2020, the U.S. plans sold 739,869 shares of the Company’s common stock to the Company to take the number of shares of the Company’s stock in the U.S. plans to zero as of December 31, 2020. No shares of the Company’s stock were purchased by the U.S. plans in 2021 or 2020. The plans received no dividends on the Company’s common stock in either 2021 or 2020. Other Retiree Benefits The Company and certain of its subsidiaries provide health care and life insurance benefits for retired employees to the extent not provided by government-sponsored plans. The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2021 2020 2021 2020 2021 2020 United States International Change in Benefit Obligations Benefit obligations at beginning of year $ 2,363 $ 2,272 $ 1,013 $ 876 $ 1,112 $ 1,050 Service cost — 1 19 17 26 20 Interest cost 61 74 20 21 35 37 Participants’ contributions — — 6 5 — — Acquisitions/plan amendments (2) — — 30 — — Actuarial loss (gain) (52) 171 (39) 65 (50) 61 Foreign exchange impact — — (38) 46 (8) (9) Termination benefits — 3 — — — — Curtailments and settlements (5) (3) (4) (7) — — Benefit payments (158) (155) (40) (40) (35) (47) Other — — — — — — Benefit obligations at end of year $ 2,207 $ 2,363 $ 937 $ 1,013 $ 1,080 $ 1,112 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,921 $ 1,806 $ 698 $ 586 $ 3 $ 37 Actual return on plan assets 46 243 45 59 — 2 Company contributions 28 30 33 36 32 11 Participants’ contributions — — 6 5 — — Foreign exchange impact — — (14) 26 — — Settlements and acquisitions (3) (3) (5) 26 — — Benefit payments (158) (155) (40) (40) (35) (47) Other — — — — — — Fair value of plan assets at end of year $ 1,834 $ 1,921 $ 723 $ 698 $ — $ 3 Funded Status Benefit obligations at end of year $ 2,207 $ 2,363 $ 937 $ 1,013 $ 1,080 $ 1,112 Fair value of plan assets at end of year 1,834 1,921 723 698 — 3 Net amount recognized $ (373) $ (442) $ (214) $ (315) $ (1,080) $ (1,109) Amounts Recognized in Balance Sheet Noncurrent assets $ 70 $ 20 $ 72 $ 18 $ — $ — Current liabilities (27) (30) (13) (14) (47) (45) Noncurrent liabilities (416) (432) (273) (319) (1,033) (1,064) Net amount recognized $ (373) $ (442) $ (214) $ (315) $ (1,080) $ (1,109) Amounts Recognized in Accumulated Other Comprehensive Income (Loss) Actuarial loss $ 866 $ 902 $ 179 $ 255 $ 356 $ 429 Transition/prior service cost — 1 9 7 — — $ 866 $ 903 $ 188 $ 262 $ 356 $ 429 Accumulated benefit obligation $ 2,171 $ 2,325 $ 872 $ 946 $ — $ — Pension Plans Other Retiree Benefit Plans 2021 2020 2021 2020 2021 2020 United States International Weighted-Average Assumptions Used to Determine Benefit Obligations Discount rate 2.98 % 2.65 % 2.10 % 1.61 % 3.06 % 2.88 % Expected long-term rate of return on plan assets 5.70 % 5.70 % 2.72 % 2.93 % N/A 5.70 % Long-term rate of compensation increase 3.50 % 3.50 % 2.89 % 2.62 % 3.50 % 3.50 % ESOP growth rate — % — % — % — % 6.00 % 10.00 % Medical cost trend rate of increase — % — % — % — % 6.00 % 6.00 % Interest Crediting Rate 2.85 % 2.48 % 0.84 % 0.83 % — % — % The actuarial gains recorded during 2021 for both the U.S. pension and other retiree benefit plans were primarily a result of an increase in discount rates applied against future estimated benefit payments that resulted in a decrease in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The actuarial losses incurred during 2020 were primarily driven by a decrease in discount rates applied against future expected benefit payments that resulted in an increase in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The overall investment objective of the plans is to balance risk and return so that obligations to employees are met. The Company evaluates its expected long-term rate of return on plan assets on an annual basis. In determining the expected long-term rate of return, the Company considers the nature of the plans’ investments and the historical rates of return. The assumed expected long-term rate of return on plan assets as of December 31, 2021 for the U.S. plans was 5.70%. Average annual rates of return for the U.S. plans for the most recent 1-year, 5-year, 10-year, 15-year and 25-year periods were 3%, 8%, 8%, 6% and 7%, respectively. Similar assessments were performed in determining rates of return on international pension plan assets to arrive at the Company’s 2021 weighted-average expected long-term rate of return on plan assets of 2.72%. The medical cost trend rate of increase assumed in measuring the expected cost of benefits is projected to decrease from 6.00% in 2022 to 4.75% by 2026, remaining at 4.75% for the years thereafter. Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following: 2021 2020 Benefit Obligation Exceeds Fair Value of Plan Assets Projected benefit obligation $ 805 $ 1,092 Fair value of plan assets 82 299 Accumulated benefit obligation 771 882 Fair value of plan assets 81 134 Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following: 2021 2020 Benefit Obligation Exceeds Fair Value of Plan Assets Accumulated postretirement benefit obligation $ 1,080 $ 1,112 Fair value of plan assets — 3 Summarized information regarding the net periodic benefit costs for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2021 2020 2019 2021 2020 2019 2021 2020 2019 United States International Components of Net Periodic Benefit Cost Service cost $ — $ 1 $ 1 $ 19 $ 17 $ 14 $ 26 $ 20 $ 15 Interest cost 61 74 90 20 21 22 35 37 41 Expected return on plan assets (106) (111) (103) (20) (22) (19) — (2) (3) Amortization of transition and prior service costs (credits) — — — 1 — 1 — — — Amortization of actuarial loss 47 46 51 11 9 9 23 18 11 Net periodic benefit cost $ 2 $ 10 $ 39 $ 31 $ 25 $ 27 $ 84 $ 73 $ 64 Other postretirement charges (3) 4 7 1 — 1 — — — Total pension cost $ (1) $ 14 $ 46 $ 32 $ 25 $ 28 $ 84 $ 73 $ 64 Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost Discount rate 2.65 % 3.40 % 4.38 % 1.61 % 2.06 % 2.80 % 2.88 % 3.56 % 4.43 % Expected long-term rate of return on plan assets 5.70 % 6.30 % 6.60 % 2.93 % 3.38 % 4.06 % 5.70 % 6.30 % 6.60 % Long-term rate of compensation increase 3.50 % 3.50 % 3.50 % 2.62 % 2.83 % 2.86 % — % — % — % ESOP growth rate — % — % — % — % — % — % 10.00 % 10.00 % 10.00 % Medical cost trend rate of increase — % — % — % — % — % — % 6.00 % 6.00 % 6.00 % Interest Crediting Rate 2.48 % 3.21 % 4.26 % 0.83 % 0.85 % 0.85 % — % — % — % The service related component of pension and other postretirement benefit costs is included in Operating profit. The non-service related components (interest cost, expected return on assets and amortization of actuarial gains and losses) are included in the line item “Non-service related postretirement costs,” which is below Operating profit. The Company made no voluntary contributions in 2021 and 2020, and made voluntary contributions of $113 in 2019, to its U.S. retirement plans. Expected Contributions and Benefit Payments The Company does not expect to make any voluntary contributions to its U.S. postretirement plans for the year ending December 31, 2022. Actual funding may differ from current estimates depending on the variability of the market value of the assets as compared to the obligation and other market or regulatory conditions. Benefit payments expected to be paid from the Company’s assets to participants in unfunded plans are estimated to be approximately $89 for the year ending December 31, 2022. Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows: Pension Plans Years Ended December 31, United States International Other Retiree Benefit Plans Total 2022 $ 147 $ 43 $ 47 $ 237 2023 146 40 48 234 2024 147 45 49 241 2025 144 44 50 238 2026 147 46 51 244 2027-2031 692 246 267 1,205

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of Income before income taxes are as follows for the years ended December 31: 2021 2020 2019 United States $ 1,256 $ 1,317 $ 1,050 International 1,831 2,330 2,251 Total Income before income taxes $ 3,087 $ 3,647 $ 3,301 The Provision for income taxes consists of the following for the years ended December 31: 2021 2020 2019 United States $ 228 $ 259 $ 180 International 521 528 594 Total Provision for income taxes $ 749 $ 787 $ 774 Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows: 2021 2020 2019 Goodwill and intangible assets $ 50 $ 1 $ 34 Property, plant and equipment (19) 12 12 Pension and other retiree benefits (4) 10 (13) Stock-based compensation 11 (7) (1) Right-of-use assets/lease liabilities (2) (1) — Tax credits and tax loss carryforwards (2) (1) 3 Deferred withholding tax (16) 111 (21) Other, net 19 18 (33) Total deferred tax benefit (provision) $ 37 $ 143 $ (19) The difference between the statutory U.S. federal income tax rate and the Company’s global effective tax rate as reflected in the Consolidated Statements of Income is as follows: 2021 2020 2019 Percentage of Income before income taxes Tax at United States statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 1.1 1.0 0.6 Earnings taxed at other than United States statutory rate 2.7 3.3 4.6 Benefit for foreign tax matters (1) — (2.0) (0.9) Non-deductible goodwill impairment charges 2.2 — — Foreign-derived intangible income benefit (2.2) (1.6) (1.3) Other, net (0.5) (0.1) (0.6) Effective tax rate 24.3 % 21.6 % 23.4 % _________ (1) In 2020, the provision for income taxes includes $71 of income tax benefits recorded on a discrete period basis, of which $45 relates to previously recorded foreign withholding taxes and $26 relates to a previously recorded valuation allowance against a deferred tax asset. As part of a previously recorded charge for the Tax Cuts and Jobs Act of 2017 (the “TCJA”), the Company has provided for foreign withholding taxes expected to be paid on the remittance of earnings from certain overseas subsidiaries no longer deemed indefinitely reinvested. As a result of a recent reorganization of the ownership structure of certain foreign subsidiaries, the Company determined that no withholding taxes will be due on the remittance by certain subsidiaries of earnings previously deemed reinvested and, accordingly, reversed $45 of previously recorded foreign withholding taxes. Also as part of the previously recorded charge for the TCJA, the Company provided a valuation allowance against a deferred tax asset related to the foreign tax credit carryforwards that the Company did not expect to be able to use due to changes made by the TCJA. As a result of a new operating structure being implemented within one of the Company’s divisions, the Company believes the use of these foreign tax credit carryforwards will not be limited in the future and, accordingly, reversed the previously recorded valuation allowance of $26. In 2019, the provision for income taxes includes a net benefit of $29 related to changes enacted by the Swiss government to its corporate tax regime, which included, among other items, the repeal of certain preferential tax regimes and an increase to the cantonal tax rate for future periods. Additionally, the government provided transition rules which allowed companies to record goodwill for tax purposes, partially offsetting the impact on cash taxes of the higher cantonal rate over the next ten years. The components of deferred tax assets (liabilities) are as follows at December 31: 2021 2020 Deferred tax liabilities: Goodwill and intangible assets $ (523) $ (603) Property, plant and equipment (301) (281) Right-of-use assets (125) (131) Deferred withholding tax (111) (95) Other (35) (52) Total deferred tax liabilities (1,095) (1,162) Deferred tax assets: Pension and other retiree benefits 344 404 Tax credits and tax loss carryforwards 152 127 Lease liabilities 138 144 Accrued liabilities 234 250 Stock-based compensation 76 73 Other 69 125 Total deferred tax assets 1,013 1,123 Valuation Allowance $ (120) $ (96) Net deferred tax assets $ 893 $ 1,027 Net deferred income taxes $ (202) $ (135) Applicable U.S. income and foreign withholding taxes have been provided on substantially all of the Company’s accumulated earnings of foreign subsidiaries. Net tax expense of $(146) was recorded directly through equity in 2021, and net tax benefits of $101 and $13 were recorded directly through equity in 2020 and 2019, respectively. The net tax expense or benefit in each year predominantly includes current and future tax impacts related to benefit plans and the impact of currency translation adjustments. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. Unrecognized tax benefits activity for the years ended December 31, 2021, 2020 and 2019 is summarized below: 2021 2020 2019 Unrecognized tax benefits: Balance, January 1 $ 227 $ 173 $ 190 Increases as a result of tax positions taken during the current year 26 18 14 Decreases of tax positions taken during prior years (20) (5) (21) Increases of tax positions taken during prior years 40 57 20 Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations (23) (19) (30) Effect of foreign currency rate movements (5) 3 — Balance, December 31 $ 245 $ 227 $ 173 If all of the unrecognized tax benefits for 2021 above were recognized, approximately $235 would impact the effective tax rate. Although it is possible that the amount of unrecognized benefits with respect to our uncertain tax positions will increase or decrease in the next twelve months, the Company does not expect material changes. The Company recognized expense of approximately $10, $9 and $0 for interest and penalties related to the above unrecognized tax benefits within income tax expense in 2021, 2020 and 2019, respectively. The Company had accrued interest and penalties of approximately $35, $24 and $23 as of December 31, 2021, 2020 and 2019, respectively. The Company and its subsidiaries file U.S. federal income tax returns as well as income tax returns in many state and foreign jurisdictions. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013, the settlement of which is not expected to have a material effect on the Company’s results of operations, cash flows or financial condition. With a few exceptions, the Company is no longer subject to U.S. state and local income tax examinations for income tax returns through December 31, 2016. In addition, the Company has subsidiaries in various foreign jurisdictions that have statutes of limitations for tax audits generally ranging from three The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share For the years ended December 31, 2021, 2020 and 2019, earnings per share were as follows: 2021 2020 2019 Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Basic EPS $ 2,166 845.0 $ 2.56 $ 2,695 856.8 $ 3.15 $ 2,367 859.1 $ 2.76 Stock options and restricted stock units 3.3 2.5 2.0 Diluted EPS $ 2,166 848.3 $ 2.55 $ 2,695 859.3 $ 3.14 $ 2,367 861.1 $ 2.75 Basic earnings per common share is computed by dividing net income available for common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding stock options and restricted stock units. As of December 31, 2021, 2020 and 2019, the average number of stock options that were anti-dilutive and not included in diluted earnings per share calculations were 2,495,393, 3,257,310 and 19,901,202, respectively. As of December 31, 2021, 2020 and 2019, the average number of restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 126,378, 25,381 and 4,516, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies As of December 31, 2021, the Company has various contractual commitments for future multi-year purchases of raw, packaging and other materials totaling approximately $724. As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. Management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites. The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances. The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is $0 to approximately $425 (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate range may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above. Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year. Brazilian Matters There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the “Seller”). The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately $106. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001. In each of September 2015, February 2017, June 2018, April 2019 and September 2020, the Company lost an administrative appeal and subsequently filed an appeal in Brazilian federal court. Currently, there are five appeals pending in the Brazilian federal court. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the disallowances are without merit and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously. In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the Company should ultimately prevail in this action. The Company is challenging this action vigorously. In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately $47, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the tax assessment is without merit and that the Company should ultimately prevail. The Company is challenging this assessment vigorously. Competition Matter Certain of the Company’s subsidiaries were historically subject to actions and, in some cases, fines, by governmental authorities in a number of countries related to alleged competition law violations. Substantially all of these matters also involved other consumer goods companies and/or retail customers. The Company’s policy is to comply with antitrust and competition laws and, if a violation of any such laws is found, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. The status as of December 31, 2021 of such competition law matters pending against the Company during the year ended December 31, 2021 is set forth below. ▪ In July 2014, the Greek competition law authority issued a statement of objections alleging a restriction of parallel imports into Greece. The Company responded to this statement of objections. In July 2017, the Company received the decision from the Greek competition law authority in which the Company was fined $11. The Company appealed the decision to the Greek courts. In April 2019, the Greek courts affirmed the judgment against the Company’s Greek subsidiary, but reduced the fine to $10.5 and dismissed the case against Colgate-Palmolive Company. The Company’s Greek subsidiary and the Greek competition authority have appealed the decision to the Greek Supreme Court. Talcum Powder Matters The Company has been named as a defendant in civil actions alleging that certain talcum powder products that were sold prior to 1996 were contaminated with asbestos and/or caused mesothelioma and other cancers. Many of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos. As of December 31, 2021, there were 171 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 136 cases as of December 31, 2020. During the year ended December 31, 2021, 74 new cases were filed and 39 cases were resolved by voluntary dismissal, settlement or dismissal by the court. The value of the settlements in the years presented was not material, either individually or in the aggregate, to each such period’s results of operations. A significant portion of the Company’s costs incurred in defending and resolving these claims has been, and the Company believes that a portion of the costs will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions, policy limits and insurance carrier insolvencies. While the Company and its legal counsel believe that these cases are without merit and intend to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters. ERISA Matter

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia. The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes. The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments. Approximately 70% of the Company’s Net sales are generated from markets outside the U.S., with approximately 45% of the Company’s Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). Oral, Personal and Home Care sales to Walmart, Inc. and its affiliates represent approximately 12%, 12% and 11% of the Company’s Net sales in 2021, 2020 and 2019, respectively. No other customer represented more than 10% of Net sales in any period presented. In 2021, Corporate Operating profit included goodwill and indefinite-lived intangible impairment charges of $571, and a benefit of $26 related to a value-added tax matter in Brazil. In 2020, Corporate Operating profit included benefits of $16 resulting from the Global Growth and Efficiency Program and a charge of $6 for acquisition-related costs. In 2019, Corporate Operating profit included charges of $125 resulting from the Global Growth and Efficiency Program, a charge of $24 for acquisition-related costs and a benefit of $30 from a value-added tax matter in Brazil. 2021 2020 2019 Net sales Oral, Personal and Home Care North America (1) $ 3,694 $ 3,741 $ 3,424 Latin America 3,663 3,418 3,606 Europe 2,841 2,747 2,450 Asia Pacific 2,867 2,701 2,707 Africa/Eurasia 1,045 981 981 Total Oral, Personal and Home Care 14,110 13,588 13,168 Pet Nutrition (2) 3,311 2,883 2,525 Total Net sales $ 17,421 $ 16,471 $ 15,693 _________ (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,391, $3,447 and $3,166 in 2021, 2020 and 2019, respectively. (2) Net sales in the U.S. for Pet Nutrition were $2,018, $1,712 and $1,441 in 2021, 2020 and 2019, respectively. 2021 2020 2019 Operating profit Oral, Personal and Home Care North America $ 754 $ 988 $ 982 Latin America 1,012 975 963 Europe 682 652 624 Asia Pacific 844 773 749 Africa/Eurasia 203 206 187 Total Oral, Personal and Home Care 3,495 3,594 3,505 Pet Nutrition 901 793 703 Corporate (1,064) (502) (654) Total Operating profit $ 3,332 $ 3,885 $ 3,554 2021 2020 2019 Capital expenditures Oral, Personal and Home Care North America $ 87 $ 65 $ 43 Latin America 118 104 90 Europe 44 41 42 Asia Pacific 50 51 40 Africa/Eurasia 33 13 8 Total Oral, Personal and Home Care 332 274 223 Pet Nutrition 147 56 41 Corporate 88 79 71 Total Capital expenditures $ 567 $ 409 $ 335 2021 2020 2019 Depreciation and amortization Oral, Personal and Home Care North America $ 104 $ 101 $ 94 Latin America 88 81 84 Europe 98 94 72 Asia Pacific 96 95 100 Africa/Eurasia 9 9 8 Total Oral, Personal and Home Care 395 380 358 Pet Nutrition 62 58 55 Corporate 99 101 106 Total Depreciation and amortization $ 556 $ 539 $ 519 2021 2020 2019 Identifiable assets Oral, Personal and Home Care North America $ 4,058 $ 4,132 $ 3,576 Latin America 2,369 2,251 2,384 Europe 4,432 5,386 5,104 Asia Pacific 2,161 2,272 2,155 Africa/Eurasia 599 605 590 Total Oral, Personal and Home Care 13,619 14,646 13,809 Pet Nutrition 1,342 1,210 1,175 Corporate (1) 79 64 50 Total Identifiable assets $ 15,040 $ 15,920 $ 15,034 ____________ (1) In 2021, Corporate identifiable assets primarily consisted of investments in equity securities (87%) and derivative instruments (10%). In 2020, Corporate identifiable assets primarily consisted of investments in equity securities (95%). In 2019, Corporate identifiable assets primarily consisted of investments in equity securities (92%) and derivative instruments (2%). 2021 2020 2019 Long-lived assets (1) United States $ 1,981 $ 1,889 $ 1,895 International 2,275 2,348 2,359 Total Long-lived assets $ 4,256 $ 4,237 $ 4,254 ____________

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Leases The Company enters into leases for land, office space, warehouses and equipment. A number of the leases include one or more options to renew the lease terms, purchase the leased property or terminate the lease. The exercise of these options is at the Company’s discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Substantially all of the Company’s leases are considered operating leases. Finance leases were not material as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the Company’s right-of use assets and liabilities for operating leases were as follows: 2021 2020 Other assets $ 527 $ 521 Other accruals 137 137 Other liabilities 451 476 Total operating lease liabilities $ 588 $ 613 Lease liabilities for operating leases as of December 31, 2021 were as follows: 2022 $ 156 2023 109 2024 76 2025 61 2026 48 Thereafter 235 Total lease commitments $ 685 Less: Interest (97) Present value of lease liabilities $ 588 The components of the Company’s operating lease cost for the twelve months ended December 31, 2021 and 2020 were as follows: 2021 2020 Operating lease cost $ 142 $ 155 Short-term lease cost 7 3 Variable lease cost 20 20 Sublease Income (1) — Total lease cost $ 168 $ 178 Short-term lease cost represents the Company’s cost with respect to leases with a duration of 12 months or less and is not reflected on the Company’s Consolidated Balance Sheets. Variable lease costs are comprised of costs, such as the Company’s proportionate share of actual costs for utilities, common area maintenance, property taxes and insurance, that are not included in the lease liability and are recognized in the period in which they are incurred. Supplemental cash flow information related to operating leases for the twelve months ended December 31, 2021 and 2020 was as follows: ▪ Payments against amounts included in the measurement of lease liabilities: $173 and $193, respectively ▪ Lease assets obtained in exchange for lease liabilities: $197 and $163, respectively. As of December 31, 2021 and 2020, the weighted-average remaining lease term for operating leases was 8 and 8 years, respectively, and the weighted-average discount rate for operating leases was 4.0% and 4.2%, respectively.

Supplemental Income Statement I

Supplemental Income Statement Information	12 Months Ended
	Dec. 31, 2021
Supplemental Income Statement Elements [Abstract]
Supplemental Income Statement Information	Supplemental Income Statement Information Other (income) expense, net 2021 2020 2019 Global Growth and Efficiency Program $ — $ (13) $ 57 Amortization of intangible assets 89 88 62 Equity income (12) (12) (9) Value-added tax matter in Brazil (26) — (30) Write-off of certain investments and fixed assets 10 — 51 Acquisition-related costs — 2 21 Charges for a change in go-to-market strategy in certain countries — — 15 Other, net 4 48 29 Total Other (income) expense, net $ 65 $ 113 $ 196 Interest (income) expense, net 2021 2020 2019 Interest incurred $ 195 $ 184 $ 193 Interest capitalized (3) (1) (1) Interest income (17) (19) (47) Total Interest (income) expense, net $ 175 $ 164 $ 145 2021 2020 2019 Research and development $ 307 $ 290 $ 281 Advertising $ 2,021 $ 1,948 $ 1,694

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Inventories by major class are as follows at December 31: Inventories 2021 2020 Raw materials and supplies $ 505 $ 454 Work-in-process 39 45 Finished goods 1,248 1,256 Total Inventories, net $ 1,792 $ 1,755 Non-current inventory, net (100) (82) Current Inventories, net $ 1,692 $ 1,673 Inventories valued under LIFO amounted to $410 and $439 at December 31, 2021 and 2020, respectively. The excess of current cost over LIFO cost at the end of each year was $60 and $65, respectively. The liquidations of LIFO inventory quantities had no material effect on income in 2021, 2020 and 2019. Inventory classified as non-current at December 31, 2021 was recorded on the Consolidated Balance Sheets as “Other assets.” Property, plant and equipment, net 2021 2020 Land $ 163 $ 166 Buildings 1,603 1,623 Manufacturing machinery and equipment 5,527 5,409 Other equipment 1,606 1,553 8,899 8,751 Accumulated depreciation (5,169) (5,035) Total Property, plant and equipment, net $ 3,730 $ 3,716 Other accruals 2021 2020 Accrued advertising and coupon redemption $ 709 $ 728 Accrued payroll and employee benefits 353 401 Accrued taxes other than income taxes 118 116 Restructuring accrual 7 21 Pension and other retiree benefits 87 89 Lease liabilities due in one year 137 137 Accrued interest 38 39 Derivatives 6 93 Other 630 717 Total Other accruals $ 2,085 $ 2,341 Other liabilities 2021 2020 Pension and other retiree benefits $ 1,722 $ 1,815 Restructuring accrual 2 10 Long-term lease liabilities 451 476 Other 254 354 Total Other liabilities $ 2,429 $ 2,655

Supplemental Other Comprehensiv

Supplemental Other Comprehensive Income (Loss) Information	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Supplemental Other Comprehensive Income (Loss) Information	Supplemental Other Comprehensive Income (Loss) Information Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows: 2021 2020 2019 Pretax Net of Tax Pretax Net of Tax Pretax Net of Tax Cumulative translation adjustments $ (99) $ (191) $ (119) $ (30) $ 49 $ 27 Pension and other benefits: Net actuarial gain (loss), prior 102 71 (125) (97) (204) (154) Amortization of net actuarial loss, transition and prior service costs (1) 82 63 74 57 72 54 Retirement Plan and other retiree benefit 184 134 (51) (40) (132) (100) Cash flow hedges: Unrealized gains (losses) on cash flow 13 10 (3) (2) (9) (7) Reclassification of (gains) losses into net earnings on cash flow hedges (2) 7 6 — — (6) (5) Gains (losses) on cash flow hedges 20 16 (3) (2) (15) (12) Total Other comprehensive income (loss) $ 105 $ (41) $ (173) $ (72) $ (98) $ (85) _________ (1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 10, Retirement Plans and Other Retiree Benefits for additional details. (2) These (gains) losses are reclassified into Cost of sales. See Note 7, Fair Value Measurements and Financial Instruments for additional details. There were no tax impacts on Other comprehensive income (loss) attributable to Noncontrolling interests. Accumulated Other Comprehensive Income (Loss)

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Dollars in Millions) Additions Balance at Beginning of Period Charged to Costs and Expenses Other Deductions Balance at End of Period Year Ended December 31, 2021 Allowance for doubtful accounts and estimated returns $ 89 $ 35 $ — $ 46 $ 78 Valuation allowance for deferred tax assets $ 96 $ 27 $ — $ 3 $ 120 Year Ended December 31, 2020 Allowance for doubtful accounts and estimated returns $ 76 $ 16 $ — $ 3 $ 89 Valuation allowance for deferred tax assets $ 115 $ 31 $ — $ 50 $ 96 Year Ended December 31, 2019 Allowance for doubtful accounts and estimated returns $ 82 $ 6 $ — $ 12 $ 76 Valuation allowance for deferred tax assets $ 54 $ 68 $ — $ 7 $ 115

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company’s investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2021 and 2020, equity method investments included in Other assets in the Consolidated Balance Sheets were $64 and $56, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company’s assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates.
Revenue Recognition	Revenue Recognition The Company’s revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to “direct the use of” and “obtain” the benefit from our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company’s right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers. Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company’s historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company’s promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates. Sales returns are generally accepted at the Company’s discretion and are not material to the Company’s Consolidated Financial Statements. The Company’s contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are classified as Selling, general and administrative expenses and were $1,687, $1,392 and $1,275 for the years ended December 31, 2021, 2020 and 2019, respectively.
Marketing Costs	Marketing Costs The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales.
Cash and Cash equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
Inventories	Inventories The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of all other inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current “Other assets.”
Property, Plant and Equipment	Property, Plant and Equipment Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over-estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses.
Goodwill and Other Intangibles	Goodwill and Other Intangibles Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.
Income Taxes	Income Taxes The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.
Financial Instruments	Financial Instruments Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 7, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton ( “ Black-Scholes ” ) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 8, Capital Stock and Stock-Based Compensation Plans.
Currency Translation	Currency Translation The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, “Government Assistance (Topic 832).” This ASU requires increased disclosure on an annual basis about transactions with domestic, foreign, local, regional and national governments, including entities related to those governments and intergovernmental organizations, that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance. This guidance is effective for the Company beginning on January 1, 2022 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606).” This guidance is effective for the Company beginning on January 1, 2023 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In January 2021, the FASB issued ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope.” This ASU clarifies that certain optional expedients and exceptions in Topic 848 apply to derivatives that are affected by the discounting transition. This guidance was effective upon issuance for the Company and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, “Codification Improvements.” This ASU improves the consistency of the codification topics by including all disclosure guidance in the appropriate disclosure section and also clarifies the application of various provisions in the codification. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU provides optional expedients and exceptions for applying generally accepted accounting principles (“GAAP”) to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance was effective upon issuance of this ASU for contract modifications and hedging relationships on a prospective basis and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In January 2020, the FASB issued ASU No. 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, “Income taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance to improve consistent application. This guidance was effective for the Company beginning on January 1, 2021 and did not have a material impact on the Company’s Consolidated Financial Statements.
Reclassifications	ReclassificationsCertain prior year amounts have been reclassified to conform to the current year presentation.

Nature of Operations (Tables)

Nature of Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of Worldwide Sales	The Company’s principal classes of products accounted for the following percentages of worldwide Net sales for the past three years: 2021 2020 2019 Oral Care 44 % 44 % 46 % Personal Care 20 % 21 % 20 % Home Care 17 % 18 % 18 % Pet Nutrition 19 % 17 % 16 % Total 100 % 100 % 100 %

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price consideration of $351 has been allocated to the net assets acquired based on their respective estimated fair values as follows: Receivables $ 11 Inventories 13 Other assets and liabilities, net (4) Other intangible assets 160 Goodwill 171 Fair value of net assets acquired $ 351

Restructuring and Related Imp_2

Restructuring and Related Implementation Charges (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	For the year ended December 31, 2019, restructuring and related implementation charges are reflected in the Consolidated Statements of Income as follows: 2019 Cost of sales $ 8 Selling, general and administrative expenses 60 Other (income) expense, net 57 Non-service related postretirement costs 7 Total Global Growth and Efficiency Program charges, pretax $ 132 Total Global Growth and Efficiency Program charges, aftertax $ 102
Schedule of Percent of Total Restructuring Charges Related To Segment for the period	Total charges incurred for the Global Growth and Efficiency Program related to initiatives undertaken by the following reportable operating segments: Total Program 2019 Charges North America 4 % 17 % Latin America 12 % 5 % Europe 4 % 19 % Asia Pacific 6 % 4 % Africa/Eurasia (1) % 5 % Hill ’ s Pet Nutrition 2 % 8 % Corporate 73 % 42 % Total 100 % 100 %
Schedule of Restructuring and Related Costs Incurred to Date	Over the course of the Global Growth and Efficiency Program, the Company incurred total pretax charges of $1,854 ($1,380 aftertax) in connection with the implementation of various projects as follows: Total Program Charges as of December 31, 2019 Employee-Related Costs $ 706 Incremental Depreciation 128 Asset Impairments 58 Other 962 Total $ 1,854

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The net carrying value of Goodwill as of December 31, 2021 and 2020 by segment was as follows: 2021 2020 Oral, Personal and Home Care North America $ 912 $ 912 Latin America 159 171 Europe 1,902 2,415 Asia Pacific 182 190 Africa/Eurasia 114 121 Total Oral, Personal and Home Care 3,269 3,809 Pet Nutrition 15 15 Total Goodwill $ 3,284 $ 3,824
Schedule of Finite and Indefinite Lived Intangible Assets By Major Class	Other intangible assets as of December 31, 2021 and 2020 were comprised of the following: 2021 2020 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trademarks - finite life $ 891 $ (445) $ 446 $ 902 $ (422) $ 480 Other finite life intangible assets 744 (289) 455 786 (237) 549 Indefinite life intangible assets 1,561 — 1,561 1,865 — 1,865 Total Other intangible assets $ 3,196 $ (734) $ 2,462 $ 3,553 $ (659) $ 2,894

Long-Term Debt and Credit Fac_2

Long-Term Debt and Credit Facilities (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt consisted of the following at December 31: Weighted Average Interest Rate Maturities 2021 2020 Notes 1.9% 2022 - 2078 $ 5,958 $ 6,170 Commercial paper (0.4)% 2022 1,204 1,139 Finance Lease Obligations Various Various 44 34 7,206 7,343 Less: Current portion of long-term debt (12) (9) Total $ 7,194 $ 7,334
Schedule of Maturities of Long-term Debt	Excluding such obligations, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2021, were as follows: Years Ended December 31, 2022 $ 456 2023 908 2024 506 2025 135 2026 566 Thereafter 3,431

Fair Value Measurements and F_2

Fair Value Measurements and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Derivative Instruments	The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020: Assets Liabilities Account Fair Value Account Fair Value Designated derivative instruments December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020 Interest rate swap contracts Other current assets $ 5 $ — Other accruals $ — $ — Interest rate swap contracts Other assets — 14 Other liabilities — — Forward-starting interest rate swaps Other assets 20 5 Other liabilities 21 — Foreign currency contracts Other current assets 22 7 Other accruals 6 93 Commodity contracts Other current assets 2 3 Other accruals — — Total designated $ 49 $ 29 $ 27 $ 93 Other financial instruments Marketable securities Other current assets 34 37 Total other financial instruments $ 34 $ 37
Activity related to fair value hedges	The following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges as of: December 31, 2021 December 31, 2020 Long-term debt: Carrying amount of hedged item $ 405 $ 413 Cumulative hedging adjustment included in the carrying amount $ 5 $ 14
Schedule of Notional Amounts of Outstanding Derivative Positions	The following tables present the notional values as of: December 31, 2021 Foreign Foreign Currency Debt Interest Rate Swaps Forward-Starting Interest Rate Swaps Commodity Contracts Fair Value Hedges $ 566 $ — $ 400 $ — $ — $ 966 Cash Flow Hedges 873 — — 700 24 1,597 Net Investment Hedges 173 4,600 — — — 4,773 December 31, 2020 Foreign Foreign Currency Debt Interest Rate Swaps Forward-Starting Interest Rate Swaps Commodity Contracts Fair Value Hedges $ 589 $ — $ 400 $ — $ — $ 989 Cash Flow Hedges 854 — — 300 17 1,171 Net Investment Hedges 528 4,523 — — — 5,051
Derivative Instruments, Gain (Loss)	The following table presents the location and amount of gains (losses) on hedges recognized on the Company’s Consolidated Statements of Income: Twelve Months Ended December 31, 2021 2020 Cost of sales Selling, general and administrative expenses Interest (income) expense, net Cost of sales Selling, general and administrative expenses Interest (income) expense, net Gain (loss) on hedges recognized in income: Interest rate swaps designated as fair value hedges: Derivative instrument $ — $ — $ 8 $ — $ — $ (10) Hedged items — — (8) — — 10 Foreign currency contracts designated as fair value hedges: Derivative instrument — 6 — — 29 — Hedged items — (6) — — (29) — Foreign currency contracts designated as cash flow hedges: Amount reclassified from OCI (12) — — 1 — — Commodity contracts designated as cash flow hedges: Amount reclassified from OCI 5 — — (1) — — Total gain (loss) on hedges recognized in income $ (7) $ — $ — $ — $ — $ —
Schedule Of Cash Flow And Net Investment Hedges Included In Accumulated Other Comprehensive Income (Loss)	The following table presents the location and amount of unrealized gains (losses) on hedges included in OCI: Twelve Months Ended December 31, 2021 2020 Foreign currency contracts designated as cash flow hedges: Gain (loss) recognized in OCI $ 16 $ (11) Forward-starting interest rate swaps designated as cash flow hedges: Gain (loss) recognized in OCI (6) 5 Commodity contracts designated as cash flow hedges: Gain (loss) recognized in OCI 3 3 Foreign currency contracts designated as net investment hedges: Gain (loss) on instruments 30 (52) Gain (loss) on hedged items (30) 52 Foreign currency debt designated as net investment hedges: Gain (loss) on instruments 370 (356) Gain (loss) on hedged items (370) 356 Total unrealized gain (loss) on hedges recognized in OCI $ 13 $ (3)

Capital Stock and Stock-Based_2

Capital Stock and Stock-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Common and Treasury Stock Activity	A summary of common stock and treasury stock activity for the three years ended December 31 is as follows: Common Stock Outstanding Treasury Stock Balance, January 1, 2019 862,912,792 602,793,568 Common stock acquired (17,219,642) 17,219,642 Shares issued for stock options 8,145,777 (8,145,777) Shares issued for restricted stock units and other 862,852 (862,852) Balance, December 31, 2019 854,701,779 611,004,581 Common stock acquired (18,701,843) 18,701,843 Shares issued for stock options 13,018,354 (13,018,354) Shares issued for restricted stock units and other 875,311 (875,311) Balance, December 31, 2020 849,893,601 615,812,759 Common stock acquired (16,518,163) 16,518,163 Shares issued for stock options 6,357,793 (6,357,793) Shares issued for restricted stock units and other 747,053 (747,053) Balance, December 31, 2021 840,480,284 625,226,076
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	Fair value is estimated using the Black-Scholes option pricing model with the assumptions summarized in the following table: 2021 2020 2019 Expected term of options 6 years 6 years 6 years Expected volatility rate 20.3 % 21.8 % 19.2 % Risk-free interest rate 1.0 % 0.5 % 1.5 % Expected dividend yield 2.3 % 2.3 % 2.3 %
Schedule of Share-based Compensation, Performance Restricted Stock and Time-based Restricted Stock Units Activity	A summary of performance-based restricted stock unit activity for the year ended December 31, 2021 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Performance-based restricted stock units as of January 1, 2021 860 $ 73 Activity: Granted 355 70 Forfeited (189) 81 Performance-based restricted stock units as of December 31, 2021 1,026 $ 70 A summary of restricted stock unit activity during 2021 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Restricted stock units as of January 1, 2021 1,897 $ 73 Activity: Granted 749 78 Vested (674) 70 Forfeited (56) 74 Restricted stock units as of December 31, 2021 1,916 $ 76
Schedule of Share-based Compensation, Stock Options, Activity	A summary of stock option activity during 2021 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Intrinsic Value of Unexercised Options outstanding, January 1, 2021 27,530 $ 71 Granted 5,120 77 Exercised (6,358) 68 Forfeited (173) 75 Expired (24) 73 Options outstanding, December 31, 2021 26,095 72 5 $ 309 Options exercisable, December 31, 2021 16,725 $ 72 3 $ 223

Retirement Plans and Other Re_2

Retirement Plans and Other Retiree Benefits (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Schedule of Allocation of Plan Assets	The target asset allocation for the Company’s defined benefit plans is as follows: United States International Asset Category Equity securities 21 % 22 % Fixed income securities 76 % 63 % Real estate and other investments 3 % 15 % Total 100 % 100 % At December 31, 2021, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Other Retiree Cash and cash equivalents Level 1 $ 38 $ 9 $ — U.S. common stocks Level 1 — 2 — International common stocks Level 1 — 13 — Pooled funds (1) Level 1 48 116 — Fixed income securities (2) Level 2 905 67 — Guaranteed investment contracts (3) Level 2 1 51 — 992 258 — Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 361 97 — Fixed income funds (5) 469 328 — Hedge funds (6) — 8 — Multi-asset funds (7) 26 2 — Real estate funds (8) — 30 — 856 465 — Other assets and liabilities, net (9) (14) — — Total Investments $ 1,834 $ 723 $ — At December 31, 2020, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Other Retiree Cash and cash equivalents Level 1 $ 50 $ 12 $ — U.S. common stocks Level 1 — 1 — International common stocks Level 1 — 8 — Pooled funds (1) Level 1 65 117 — Fixed income securities (2) Level 2 1,117 59 2 Guaranteed investment contracts (3) Level 2 1 55 — 1,233 252 2 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 456 183 1 Fixed income funds (5) 136 225 — Hedge funds (6) — 6 — Multi-asset funds (7) 77 2 — Real estate funds (8) 34 30 — 703 446 1 Other assets and liabilities, net (9) (15) — — Total Investments $ 1,921 $ 698 $ 3 _______ (1) Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities. (2) The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2021, approximately 40% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds, compared to approximately 50% as of December 31, 2020. (3) The guaranteed investment contracts (“GICs”) represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption. (4) Investments that are measured at fair value using net asset value (“NAV”) per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly. (5) Fixed income funds primarily invest in U.S. government and investment grade corporate bonds. (6) Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options. (7) Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies. (8) Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager.
Defined Benefit Plans Disclosures	The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2021 2020 2021 2020 2021 2020 United States International Change in Benefit Obligations Benefit obligations at beginning of year $ 2,363 $ 2,272 $ 1,013 $ 876 $ 1,112 $ 1,050 Service cost — 1 19 17 26 20 Interest cost 61 74 20 21 35 37 Participants’ contributions — — 6 5 — — Acquisitions/plan amendments (2) — — 30 — — Actuarial loss (gain) (52) 171 (39) 65 (50) 61 Foreign exchange impact — — (38) 46 (8) (9) Termination benefits — 3 — — — — Curtailments and settlements (5) (3) (4) (7) — — Benefit payments (158) (155) (40) (40) (35) (47) Other — — — — — — Benefit obligations at end of year $ 2,207 $ 2,363 $ 937 $ 1,013 $ 1,080 $ 1,112 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,921 $ 1,806 $ 698 $ 586 $ 3 $ 37 Actual return on plan assets 46 243 45 59 — 2 Company contributions 28 30 33 36 32 11 Participants’ contributions — — 6 5 — — Foreign exchange impact — — (14) 26 — — Settlements and acquisitions (3) (3) (5) 26 — — Benefit payments (158) (155) (40) (40) (35) (47) Other — — — — — — Fair value of plan assets at end of year $ 1,834 $ 1,921 $ 723 $ 698 $ — $ 3 Funded Status Benefit obligations at end of year $ 2,207 $ 2,363 $ 937 $ 1,013 $ 1,080 $ 1,112 Fair value of plan assets at end of year 1,834 1,921 723 698 — 3 Net amount recognized $ (373) $ (442) $ (214) $ (315) $ (1,080) $ (1,109) Amounts Recognized in Balance Sheet Noncurrent assets $ 70 $ 20 $ 72 $ 18 $ — $ — Current liabilities (27) (30) (13) (14) (47) (45) Noncurrent liabilities (416) (432) (273) (319) (1,033) (1,064) Net amount recognized $ (373) $ (442) $ (214) $ (315) $ (1,080) $ (1,109) Amounts Recognized in Accumulated Other Comprehensive Income (Loss) Actuarial loss $ 866 $ 902 $ 179 $ 255 $ 356 $ 429 Transition/prior service cost — 1 9 7 — — $ 866 $ 903 $ 188 $ 262 $ 356 $ 429 Accumulated benefit obligation $ 2,171 $ 2,325 $ 872 $ 946 $ — $ — Pension Plans Other Retiree Benefit Plans 2021 2020 2021 2020 2021 2020 United States International Weighted-Average Assumptions Used to Determine Benefit Obligations Discount rate 2.98 % 2.65 % 2.10 % 1.61 % 3.06 % 2.88 % Expected long-term rate of return on plan assets 5.70 % 5.70 % 2.72 % 2.93 % N/A 5.70 % Long-term rate of compensation increase 3.50 % 3.50 % 2.89 % 2.62 % 3.50 % 3.50 % ESOP growth rate — % — % — % — % 6.00 % 10.00 % Medical cost trend rate of increase — % — % — % — % 6.00 % 6.00 % Interest Crediting Rate 2.85 % 2.48 % 0.84 % 0.83 % — % — %
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following: 2021 2020 Benefit Obligation Exceeds Fair Value of Plan Assets Projected benefit obligation $ 805 $ 1,092 Fair value of plan assets 82 299 Accumulated benefit obligation 771 882 Fair value of plan assets 81 134 Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following: 2021 2020 Benefit Obligation Exceeds Fair Value of Plan Assets Accumulated postretirement benefit obligation $ 1,080 $ 1,112 Fair value of plan assets — 3
Schedule of Net Benefit Costs	Summarized information regarding the net periodic benefit costs for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2021 2020 2019 2021 2020 2019 2021 2020 2019 United States International Components of Net Periodic Benefit Cost Service cost $ — $ 1 $ 1 $ 19 $ 17 $ 14 $ 26 $ 20 $ 15 Interest cost 61 74 90 20 21 22 35 37 41 Expected return on plan assets (106) (111) (103) (20) (22) (19) — (2) (3) Amortization of transition and prior service costs (credits) — — — 1 — 1 — — — Amortization of actuarial loss 47 46 51 11 9 9 23 18 11 Net periodic benefit cost $ 2 $ 10 $ 39 $ 31 $ 25 $ 27 $ 84 $ 73 $ 64 Other postretirement charges (3) 4 7 1 — 1 — — — Total pension cost $ (1) $ 14 $ 46 $ 32 $ 25 $ 28 $ 84 $ 73 $ 64 Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost Discount rate 2.65 % 3.40 % 4.38 % 1.61 % 2.06 % 2.80 % 2.88 % 3.56 % 4.43 % Expected long-term rate of return on plan assets 5.70 % 6.30 % 6.60 % 2.93 % 3.38 % 4.06 % 5.70 % 6.30 % 6.60 % Long-term rate of compensation increase 3.50 % 3.50 % 3.50 % 2.62 % 2.83 % 2.86 % — % — % — % ESOP growth rate — % — % — % — % — % — % 10.00 % 10.00 % 10.00 % Medical cost trend rate of increase — % — % — % — % — % — % 6.00 % 6.00 % 6.00 % Interest Crediting Rate 2.48 % 3.21 % 4.26 % 0.83 % 0.85 % 0.85 % — % — % — %
Schedule of Expected Benefit Payments	Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows: Pension Plans Years Ended December 31, United States International Other Retiree Benefit Plans Total 2022 $ 147 $ 43 $ 47 $ 237 2023 146 40 48 234 2024 147 45 49 241 2025 144 44 50 238 2026 147 46 51 244 2027-2031 692 246 267 1,205

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Income Before Income Taxes	The components of Income before income taxes are as follows for the years ended December 31: 2021 2020 2019 United States $ 1,256 $ 1,317 $ 1,050 International 1,831 2,330 2,251 Total Income before income taxes $ 3,087 $ 3,647 $ 3,301
Provision for Income Taxes	The Provision for income taxes consists of the following for the years ended December 31: 2021 2020 2019 United States $ 228 $ 259 $ 180 International 521 528 594 Total Provision for income taxes $ 749 $ 787 $ 774
Schedule of Components of Deferred Income Tax Benefit	Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows: 2021 2020 2019 Goodwill and intangible assets $ 50 $ 1 $ 34 Property, plant and equipment (19) 12 12 Pension and other retiree benefits (4) 10 (13) Stock-based compensation 11 (7) (1) Right-of-use assets/lease liabilities (2) (1) — Tax credits and tax loss carryforwards (2) (1) 3 Deferred withholding tax (16) 111 (21) Other, net 19 18 (33) Total deferred tax benefit (provision) $ 37 $ 143 $ (19)
Effective Tax Rate Reconciliation	The difference between the statutory U.S. federal income tax rate and the Company’s global effective tax rate as reflected in the Consolidated Statements of Income is as follows: 2021 2020 2019 Percentage of Income before income taxes Tax at United States statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 1.1 1.0 0.6 Earnings taxed at other than United States statutory rate 2.7 3.3 4.6 Benefit for foreign tax matters (1) — (2.0) (0.9) Non-deductible goodwill impairment charges 2.2 — — Foreign-derived intangible income benefit (2.2) (1.6) (1.3) Other, net (0.5) (0.1) (0.6) Effective tax rate 24.3 % 21.6 % 23.4 % _________ (1) In 2020, the provision for income taxes includes $71 of income tax benefits recorded on a discrete period basis, of which $45 relates to previously recorded foreign withholding taxes and $26 relates to a previously recorded valuation allowance against a deferred tax asset. As part of a previously recorded charge for the Tax Cuts and Jobs Act of 2017 (the “TCJA”), the Company has provided for foreign withholding taxes expected to be paid on the remittance of earnings from certain overseas subsidiaries no longer deemed indefinitely reinvested. As a result of a recent reorganization of the ownership structure of certain foreign subsidiaries, the Company determined that no withholding taxes will be due on the remittance by certain subsidiaries of earnings previously deemed reinvested and, accordingly, reversed $45 of previously recorded foreign withholding taxes. Also as part of the previously recorded charge for the TCJA, the Company provided a valuation allowance against a deferred tax asset related to the foreign tax credit carryforwards that the Company did not expect to be able to use due to changes made by the TCJA. As a result of a new operating structure being implemented within one of the Company’s divisions, the Company believes the use of these foreign tax credit carryforwards will not be limited in the future and, accordingly, reversed the previously recorded valuation allowance of $26. In 2019, the provision for income taxes includes a net benefit of $29 related to changes enacted by the Swiss government to its corporate tax regime, which included, among other items, the repeal of certain preferential tax regimes and an increase to the cantonal tax rate for future periods. Additionally, the government provided transition rules which allowed companies to record goodwill for tax purposes, partially offsetting the impact on cash taxes of the higher cantonal rate over the next ten years.
Components of Deferred Tax Assets (Liabilities)	The components of deferred tax assets (liabilities) are as follows at December 31: 2021 2020 Deferred tax liabilities: Goodwill and intangible assets $ (523) $ (603) Property, plant and equipment (301) (281) Right-of-use assets (125) (131) Deferred withholding tax (111) (95) Other (35) (52) Total deferred tax liabilities (1,095) (1,162) Deferred tax assets: Pension and other retiree benefits 344 404 Tax credits and tax loss carryforwards 152 127 Lease liabilities 138 144 Accrued liabilities 234 250 Stock-based compensation 76 73 Other 69 125 Total deferred tax assets 1,013 1,123 Valuation Allowance $ (120) $ (96) Net deferred tax assets $ 893 $ 1,027 Net deferred income taxes $ (202) $ (135)
Unrecognized Tax Benefits Activity	Unrecognized tax benefits activity for the years ended December 31, 2021, 2020 and 2019 is summarized below: 2021 2020 2019 Unrecognized tax benefits: Balance, January 1 $ 227 $ 173 $ 190 Increases as a result of tax positions taken during the current year 26 18 14 Decreases of tax positions taken during prior years (20) (5) (21) Increases of tax positions taken during prior years 40 57 20 Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations (23) (19) (30) Effect of foreign currency rate movements (5) 3 — Balance, December 31 $ 245 $ 227 $ 173

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	For the years ended December 31, 2021, 2020 and 2019, earnings per share were as follows: 2021 2020 2019 Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Basic EPS $ 2,166 845.0 $ 2.56 $ 2,695 856.8 $ 3.15 $ 2,367 859.1 $ 2.76 Stock options and restricted stock units 3.3 2.5 2.0 Diluted EPS $ 2,166 848.3 $ 2.55 $ 2,695 859.3 $ 3.14 $ 2,367 861.1 $ 2.75

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Net Sales and Operating Profit by Segment	2021 2020 2019 Net sales Oral, Personal and Home Care North America (1) $ 3,694 $ 3,741 $ 3,424 Latin America 3,663 3,418 3,606 Europe 2,841 2,747 2,450 Asia Pacific 2,867 2,701 2,707 Africa/Eurasia 1,045 981 981 Total Oral, Personal and Home Care 14,110 13,588 13,168 Pet Nutrition (2) 3,311 2,883 2,525 Total Net sales $ 17,421 $ 16,471 $ 15,693 _________ (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,391, $3,447 and $3,166 in 2021, 2020 and 2019, respectively. (2) Net sales in the U.S. for Pet Nutrition were $2,018, $1,712 and $1,441 in 2021, 2020 and 2019, respectively. 2021 2020 2019 Operating profit Oral, Personal and Home Care North America $ 754 $ 988 $ 982 Latin America 1,012 975 963 Europe 682 652 624 Asia Pacific 844 773 749 Africa/Eurasia 203 206 187 Total Oral, Personal and Home Care 3,495 3,594 3,505 Pet Nutrition 901 793 703 Corporate (1,064) (502) (654) Total Operating profit $ 3,332 $ 3,885 $ 3,554 2021 2020 2019 Capital expenditures Oral, Personal and Home Care North America $ 87 $ 65 $ 43 Latin America 118 104 90 Europe 44 41 42 Asia Pacific 50 51 40 Africa/Eurasia 33 13 8 Total Oral, Personal and Home Care 332 274 223 Pet Nutrition 147 56 41 Corporate 88 79 71 Total Capital expenditures $ 567 $ 409 $ 335 2021 2020 2019 Depreciation and amortization Oral, Personal and Home Care North America $ 104 $ 101 $ 94 Latin America 88 81 84 Europe 98 94 72 Asia Pacific 96 95 100 Africa/Eurasia 9 9 8 Total Oral, Personal and Home Care 395 380 358 Pet Nutrition 62 58 55 Corporate 99 101 106 Total Depreciation and amortization $ 556 $ 539 $ 519 2021 2020 2019 Identifiable assets Oral, Personal and Home Care North America $ 4,058 $ 4,132 $ 3,576 Latin America 2,369 2,251 2,384 Europe 4,432 5,386 5,104 Asia Pacific 2,161 2,272 2,155 Africa/Eurasia 599 605 590 Total Oral, Personal and Home Care 13,619 14,646 13,809 Pet Nutrition 1,342 1,210 1,175 Corporate (1) 79 64 50 Total Identifiable assets $ 15,040 $ 15,920 $ 15,034 ____________ (1) In 2021, Corporate identifiable assets primarily consisted of investments in equity securities (87%) and derivative instruments (10%). In 2020, Corporate identifiable assets primarily consisted of investments in equity securities (95%). In 2019, Corporate identifiable assets primarily consisted of investments in equity securities (92%) and derivative instruments (2%). 2021 2020 2019 Long-lived assets (1) United States $ 1,981 $ 1,889 $ 1,895 International 2,275 2,348 2,359 Total Long-lived assets $ 4,256 $ 4,237 $ 4,254 ____________

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Right-of-use Assets and Liabilities for Operating Leases	As of December 31, 2021 and 2020, the Company’s right-of use assets and liabilities for operating leases were as follows: 2021 2020 Other assets $ 527 $ 521 Other accruals 137 137 Other liabilities 451 476 Total operating lease liabilities $ 588 $ 613
Schedule of Operating Lease Liabilities	Lease liabilities for operating leases as of December 31, 2021 were as follows: 2022 $ 156 2023 109 2024 76 2025 61 2026 48 Thereafter 235 Total lease commitments $ 685 Less: Interest (97) Present value of lease liabilities $ 588
Schedule of Components of Operating Lease Expense	The components of the Company’s operating lease cost for the twelve months ended December 31, 2021 and 2020 were as follows: 2021 2020 Operating lease cost $ 142 $ 155 Short-term lease cost 7 3 Variable lease cost 20 20 Sublease Income (1) — Total lease cost $ 168 $ 178

Supplemental Income Statement_2

Supplemental Income Statement Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Income Statement Elements [Abstract]
Other (income) expense, net	Other (income) expense, net 2021 2020 2019 Global Growth and Efficiency Program $ — $ (13) $ 57 Amortization of intangible assets 89 88 62 Equity income (12) (12) (9) Value-added tax matter in Brazil (26) — (30) Write-off of certain investments and fixed assets 10 — 51 Acquisition-related costs — 2 21 Charges for a change in go-to-market strategy in certain countries — — 15 Other, net 4 48 29 Total Other (income) expense, net $ 65 $ 113 $ 196
Interest expense, net	Interest (income) expense, net 2021 2020 2019 Interest incurred $ 195 $ 184 $ 193 Interest capitalized (3) (1) (1) Interest income (17) (19) (47) Total Interest (income) expense, net $ 175 $ 164 $ 145
Research and development and Advertising	2021 2020 2019 Research and development $ 307 $ 290 $ 281 Advertising $ 2,021 $ 1,948 $ 1,694

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventories by Major Class	Inventories by major class are as follows at December 31: Inventories 2021 2020 Raw materials and supplies $ 505 $ 454 Work-in-process 39 45 Finished goods 1,248 1,256 Total Inventories, net $ 1,792 $ 1,755 Non-current inventory, net (100) (82) Current Inventories, net $ 1,692 $ 1,673
Schedule of Property, Plant and Equipment	Property, plant and equipment, net 2021 2020 Land $ 163 $ 166 Buildings 1,603 1,623 Manufacturing machinery and equipment 5,527 5,409 Other equipment 1,606 1,553 8,899 8,751 Accumulated depreciation (5,169) (5,035) Total Property, plant and equipment, net $ 3,730 $ 3,716
Schedule of Other Accruals	Other accruals 2021 2020 Accrued advertising and coupon redemption $ 709 $ 728 Accrued payroll and employee benefits 353 401 Accrued taxes other than income taxes 118 116 Restructuring accrual 7 21 Pension and other retiree benefits 87 89 Lease liabilities due in one year 137 137 Accrued interest 38 39 Derivatives 6 93 Other 630 717 Total Other accruals $ 2,085 $ 2,341
Schedule of Other Liabilities	Other liabilities 2021 2020 Pension and other retiree benefits $ 1,722 $ 1,815 Restructuring accrual 2 10 Long-term lease liabilities 451 476 Other 254 354 Total Other liabilities $ 2,429 $ 2,655

Supplemental Other Comprehens_2

Supplemental Other Comprehensive Income (Loss) Information (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Comprehensive Income (Loss)	Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows: 2021 2020 2019 Pretax Net of Tax Pretax Net of Tax Pretax Net of Tax Cumulative translation adjustments $ (99) $ (191) $ (119) $ (30) $ 49 $ 27 Pension and other benefits: Net actuarial gain (loss), prior 102 71 (125) (97) (204) (154) Amortization of net actuarial loss, transition and prior service costs (1) 82 63 74 57 72 54 Retirement Plan and other retiree benefit 184 134 (51) (40) (132) (100) Cash flow hedges: Unrealized gains (losses) on cash flow 13 10 (3) (2) (9) (7) Reclassification of (gains) losses into net earnings on cash flow hedges (2) 7 6 — — (6) (5) Gains (losses) on cash flow hedges 20 16 (3) (2) (15) (12) Total Other comprehensive income (loss) $ 105 $ (41) $ (173) $ (72) $ (98) $ (85) _________ (1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 10, Retirement Plans and Other Retiree Benefits for additional details. (2) These (gains) losses are reclassified into Cost of sales. See Note 7, Fair Value Measurements and Financial Instruments for additional details.

Nature of Operations (Details)

Nature of Operations (Details) - business_segment	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of product segments (in segments)	2
Sales Revenue, Net | Product Concentration Risk
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	100.00%	100.00%	100.00%
Sales Revenue, Net | Product Concentration Risk | Oral Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	44.00%	44.00%	46.00%
Sales Revenue, Net | Product Concentration Risk | Personal Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	20.00%	21.00%	20.00%
Sales Revenue, Net | Product Concentration Risk | Home Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	17.00%	18.00%	18.00%
Sales Revenue, Net | Product Concentration Risk | Pet Nutrition
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	19.00%	17.00%	16.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Principles of Consolidation, Shipping and Handling Costs, Inventories, & Property, Plant, and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Investments accounted for using the equity method, minimum interest	20.00%
Investments accounted for using the equity method, maximum interest	50.00%
Equity method investments included in other assets	$ 64	$ 56
Investments accounted for using the cost method, maximum interest	20.00%
Approximate percentage of inventories determined using the first-in, first-out (FIFO) method	75.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details) - Local Brands, Trademarks, Customer Relationships, and Non-Compete Agreements	12 Months Ended
	Dec. 31, 2021
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangible assets	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangible assets	40 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Selling, general and administrative expenses	$ 6,407	$ 6,019	$ 5,575
Minimum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Shipping and Handling
Property, Plant and Equipment [Line Items]
Selling, general and administrative expenses	$ 1,687	$ 1,392	$ 1,275

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Millions	Jan. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 3,284	$ 3,824
hello
Business Acquisition [Line Items]
Payments to acquire business	$ 351
Purchase price consideration	351
Other intangible assets	160
Goodwill	171
hello | North America
Business Acquisition [Line Items]
Goodwill	171
hello | Trademarks
Business Acquisition [Line Items]
Other intangible assets	$ 115
Useful life	25 years
hello | Customer Relationships
Business Acquisition [Line Items]
Other intangible assets	$ 45
Useful life	17 years

Acquisitions - Schedule of Reco

Acquisitions - Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 3,284	$ 3,824
hello
Business Acquisition [Line Items]
Receivables			$ 11
Inventories			13
Other assets and liabilities, net			(4)
Other intangible assets			160
Goodwill			171
Fair value of net assets acquired			$ 351

Restructuring and Related Imp_3

Restructuring and Related Implementation Charges - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 27, 2022
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program		$ 0	$ (13)	$ 57
Global Productivity Initiative | Subsequent Event
Restructuring Cost and Reserve [Line Items]
Restructuring and related Cost, estimated to settle through cash, percentage					90.00%
Global Productivity Initiative | Subsequent Event | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage					80.00%
Global Productivity Initiative | Subsequent Event | Asset Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage					10.00%
Global Productivity Initiative | Subsequent Event | Other Charges
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage					10.00%
Global Productivity Initiative | Minimum | Subsequent Event
Restructuring Cost and Reserve [Line Items]
Restructuring program cost before tax					$ 200
Global Productivity Initiative | Maximum | Subsequent Event
Restructuring Cost and Reserve [Line Items]
Restructuring program cost before tax					$ 240
Global Growth and Efficiency Program
Restructuring Cost and Reserve [Line Items]
Restructuring reduction	$ 16
Restructuring reduction after tax	13
Pretax charges related to the Restructuring Program to date				1,854
Restructuring and related cost incurred cost to date after tax				1,380
Global Growth and Efficiency Program				132
Global Growth and Efficiency Program | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date				706
Global Growth and Efficiency Program | Other Charges
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date				962
Global Growth and Efficiency Program | Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring reduction	3
Global Growth and Efficiency Program				60
Global Growth and Efficiency Program | Other (income) expense, net
Restructuring Cost and Reserve [Line Items]
Restructuring reduction	$ 13
Global Growth and Efficiency Program				$ 57

Restructuring and Related Imp_4

Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program	$ 0	$ (13)	$ 57
Global Growth and Efficiency Program
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program			132
Restructuring And Related Cost, Incurred Cost, After Tax			102
Global Growth and Efficiency Program | Cost of sales
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program			8
Global Growth and Efficiency Program | Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program			60
Global Growth and Efficiency Program | Other (income) expense, net
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program			57
Global Growth and Efficiency Program | Non-service related postretirement costs
Restructuring Cost and Reserve [Line Items]
Global Growth and Efficiency Program			$ 7

Restructuring and Related Imp_5

Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details) - Global Growth and Efficiency Program	12 Months Ended
	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	100.00%
Percent of restructuring charges related to segment, total program accumulated charges	100.00%
Pet Nutrition
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	2.00%
Percent of restructuring charges related to segment, total program accumulated charges	8.00%
Corporate
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	73.00%
Percent of restructuring charges related to segment, total program accumulated charges	42.00%
North America
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	4.00%
Percent of restructuring charges related to segment, total program accumulated charges	17.00%
Latin America
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	12.00%
Percent of restructuring charges related to segment, total program accumulated charges	5.00%
Europe
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	4.00%
Percent of restructuring charges related to segment, total program accumulated charges	19.00%
Asia Pacific
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	6.00%
Percent of restructuring charges related to segment, total program accumulated charges	4.00%
Africa/Eurasia
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	(1.00%)
Percent of restructuring charges related to segment, total program accumulated charges	5.00%

Restructuring and Related Imp_6

Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details) - Global Growth and Efficiency Program $ in Millions	Dec. 31, 2019USD ($)
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	$ 1,854
Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	706
Incremental Depreciation
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	128
Asset Impairments
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	58
Other
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	$ 962

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Goodwill	$ 3,284	$ 3,824
Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	3,269	3,809
Pet Nutrition
Goodwill [Line Items]
Goodwill	15	15
North America | Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	912	912
Latin America | Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	159	171
Europe | Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	1,902	2,415
Asia Pacific | Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	182	190
Africa/Eurasia | Oral, Personal and Home Care
Goodwill [Line Items]
Goodwill	$ 114	$ 121

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finite and indefinite-lived intangible assets [Line Items]
Finite & indefinite lived intangibles, gross	$ 3,196	$ 3,553
Finite-lived intangible assets, accumulated amortization, net	(734)	(659)
Intangible assets, net (excluding goodwill)	2,462	2,894
Indefinite life intangible assets
Finite and indefinite-lived intangible assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	1,561	1,865
Trademarks
Finite and indefinite-lived intangible assets [Line Items]
Finite-lived intangible assets, gross	891	902
Finite-lived intangible assets, accumulated amortization, net	(445)	(422)
Finite-lived intangible assets, net	446	480
Other finite life intangible assets
Finite and indefinite-lived intangible assets [Line Items]
Finite-lived intangible assets, gross	744	786
Finite-lived intangible assets, accumulated amortization, net	(289)	(237)
Finite-lived intangible assets, net	$ 455	$ 549

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Amortization of intangible assets		$ 89	$ 88	$ 62
Annual estimated amortization expense, year 1	$ 77	77
Annual estimated amortization expense, year 2	77	77
Annual estimated amortization expense, year 3	77	77
Annual estimated amortization expense, year 4	77	77
Annual estimated amortization expense, year 5	77	77
Impairment charge	204
Reporting unit, impairment analysis, projected reduction of carrying amount	588	588
Filorga Reporting Unit
Goodwill [Line Items]
Goodwill, Impairment Loss	367
Carrying value (including goodwill)	$ 577	$ 577

Long-Term Debt and Credit Fac_3

Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt	$ 7,206	$ 7,343
Less: Current portion of long-term debt	(12)	(9)
Total debt, excluding current portion of long-term debt	$ 7,194	7,334
Notes
Debt Instrument [Line Items]
Weighted average interest rate	1.90%
Total debt	$ 5,958	6,170
Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate	(0.40%)
Total debt	$ 1,204	1,139
Finance Lease Obligations
Debt Instrument [Line Items]
Total debt	$ 44	$ 34

Long-Term Debt and Credit Fac_4

Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities (Details) $ in Millions	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 456
2023	908
2024	506
2025	135
2026	566
Thereafter	$ 3,431

Long-Term Debt and Credit Fac_5

Long-Term Debt and Credit Facilities - Narrative (Details)	1 Months Ended	3 Months Ended			12 Months Ended
	Aug. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 1990CAD ($)
Debt Instrument [Line Items]
Weighted-average interest rate on short term borrowings		0.70%		4.80%	0.70%	4.80%		0.70%
Debt instrument term					364 days
Loss on early extinguishment of debt					$ 75,000,000	$ 23,000,000	$ 0
Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument term	5 years
Unused borrowing capacity		$ 3,457,000,000			3,457,000,000
Long-term Line of Credit	$ 3,000,000,000
Amended Domestic Revolving Credit Facility 2650 Million Capacity
Debt Instrument [Line Items]
Maximum borrowing capacity		2,650,000,000			2,650,000,000
Amended Foreign Revolving Credit Facility 1500 Million Capacity
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,500,000,000			$ 1,500,000,000
Eight Year notes at 0.30 Percent
Debt Instrument [Line Items]
Face amount | €								€ 500,000,000
Debt instrument term		8 years
Fixed interest rate		0.30%			0.30%			0.30%
2.45% Notes Due 2021
Debt Instrument [Line Items]
Fixed interest rate		0.00%		2.45%	0.00%	2.45%		0.00%
Repayments of Debt				$ 300,000,000
12.85% Guaranteed Notes Due 2030
Debt Instrument [Line Items]
Face amount									$ 145,000
Fixed interest rate									12.85%
0.00% Notes Due 2021
Debt Instrument [Line Items]
Face amount		$ 500,000,000			$ 500,000,000
Loss on early extinguishment of debt			$ 75,000,000
2.30% Notes Due 2022
Debt Instrument [Line Items]
Fixed interest rate				2.30%		2.30%
Repayments of Debt				$ 500,000,000
2.45% Notes Due 2021 and 2.30% Notes Due 2022
Debt Instrument [Line Items]
Loss on early extinguishment of debt				$ 23,000,000

Fair Value Measurements and F_3

Fair Value Measurements and Financial Instruments - Narrative (Details)	12 Months Ended
	Dec. 31, 2021USD ($)country_and_territory	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Minimum number of countries and territories serving consumers (more than) (in countries and territories) | country_and_territory	200
Carrying Value
Debt Instrument [Line Items]
Carrying value of long-term debt	$ 7,206,000,000	$ 7,343,000,000
Fair Value, Inputs, Level 2
Debt Instrument [Line Items]
Estimated fair value of long-term debt	$ 7,651,000,000	$ 8,175,000,000

Fair Value Measurements and F_4

Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Designated derivative instruments
Derivative asset	$ 49	$ 29
Derivative liability	27	93
Other financial instruments
Investments fair value	34	37
Other assets | Interest rate swap contracts
Designated derivative instruments
Derivative asset	0	14
Other assets | Forward-starting interest rate swaps
Designated derivative instruments
Derivative asset	20	5
Other current assets
Other financial instruments
Marketable securities	34	37
Other current assets | Interest rate swap contracts
Designated derivative instruments
Derivative asset	5	0
Other current assets | Foreign currency contracts
Designated derivative instruments
Derivative asset	22	7
Other current assets | Commodity contracts
Designated derivative instruments
Derivative asset	2	3
Other liabilities | Interest rate swap contracts
Designated derivative instruments
Derivative liability	0	0
Other liabilities | Forward-starting interest rate swaps
Designated derivative instruments
Derivative liability	21	0
Other accruals | Interest rate swap contracts
Designated derivative instruments
Derivative liability	0	0
Other accruals | Foreign currency contracts
Designated derivative instruments
Derivative liability	6	93
Other accruals | Commodity contracts
Designated derivative instruments
Derivative liability	$ 0	$ 0

Fair Value Measurements and F_5

Fair Value Measurements and Financial Instruments - Carrying Value and Estimated Fair Value of Long-term Debt (Details) - Long-term Debt - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Carrying amount of hedged item	$ 405	$ 413
Cumulative hedging adjustment included in the carrying amount	$ 5	$ 14

Fair Value Measurements and F_6

Fair Value Measurements and Financial Instruments - Schedule of Notional Values (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	$ 966	$ 989
Fair Value Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	566	589
Fair Value Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Fair Value Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	400	400
Fair Value Hedges | Forward-starting interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Fair Value Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	1,597	1,171
Cash Flow Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	873	854
Cash Flow Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Cash Flow Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Cash Flow Hedges | Forward-starting interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	700	300
Cash Flow Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	24	17
Net Investment Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	4,773	5,051
Net Investment Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	173	528
Net Investment Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	4,600	4,523
Net Investment Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Net Investment Hedges | Forward-starting interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Net Investment Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	$ 0	$ 0

Fair Value Measurements and F_7

Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) on Hedges Recognized in Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Total gain (loss) on hedges recognized in income	$ (7)	$ 0
Cost of sales | Fair Value Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	0	0
Gain (loss) on hedged items	0	0
Cost of sales | Fair Value Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	0	0
Gain (loss) on hedged items	0	0
Cost of sales | Cash Flow Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	(12)	1
Cost of sales | Cash Flow Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	5	(1)
Selling, general and administrative expenses
Derivative Instruments, Gain (Loss) [Line Items]
Total gain (loss) on hedges recognized in income	0	0
Selling, general and administrative expenses | Fair Value Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	0	0
Gain (loss) on hedged items	0	0
Selling, general and administrative expenses | Fair Value Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	6	29
Gain (loss) on hedged items	(6)	(29)
Selling, general and administrative expenses | Cash Flow Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	0	0
Selling, general and administrative expenses | Cash Flow Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	0	0
Interest (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Total gain (loss) on hedges recognized in income	0	0
Interest (income) expense, net | Fair Value Hedges | Interest rate swap contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	8	(10)
Gain (loss) on hedged items	(8)	10
Interest (income) expense, net | Fair Value Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instrument	0	0
Gain (loss) on hedged items	0	0
Interest (income) expense, net | Cash Flow Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	0	0
Interest (income) expense, net | Cash Flow Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from OCI	$ 0	$ 0

Fair Value Measurements and F_8

Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) Included in OCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flow hedges [Abstract]
Gain (loss) recognized in OCI	$ 13	$ (3)
Foreign currency contracts
Cash flow hedges [Abstract]
Gain (loss) recognized in OCI	16	(11)
Net investment hedges [Abstract]
Gain (loss) on instruments	30	(52)
Gain (loss) on hedged items	(30)	52
Forward-starting interest rate swaps
Cash flow hedges [Abstract]
Gain (loss) recognized in OCI	(6)	5
Commodity contracts
Cash flow hedges [Abstract]
Gain (loss) recognized in OCI	3	3
Foreign Currency Debt
Net investment hedges [Abstract]
Gain (loss) on instruments	370	(356)
Gain (loss) on hedged items	$ (370)	$ 356

Capital Stock and Stock-Based_3

Capital Stock and Stock-Based Compensation Plans - Narrative (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)plan$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Jun. 18, 2018USD ($)
Preference Stock [Abstract]
Shares authorized (in shares) | shares	50,262,150
Stock Repurchases [Abstract]
Repurchased stock	$ 1,320	$ 1,476	$ 1,202
Stock-Based Compensation [Abstract]
Number of stockholder approved plans, current | plan	1
Total stock-based compensation expense charged against pretax income	$ 135	107	100
Total income tax benefit from stock compensation	$ 25	$ 20	$ 20
Weighted-average estimated fair value of stock options granted (in dollars per share) | $ / shares	$ 11.11	$ 11.26	$ 10.48
Stock-based compensation, additional disclosures [Abstract]
Tax benefit from exercise of stock options and vesting of restricted stock unit awards	$ 9	$ 8	$ 6
Proceeds from exercise of stock options	$ 424	$ 874	498
Stock Option Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Vesting period (in years)	3 years
Unrecognized compensation expense	$ 32
Number of shares available for grant (in shares) | shares	26,038,000
Unrecognized compensation expense, weighted-average period of recognition in years	1 year 6 months
Stock-based compensation, additional disclosures [Abstract]
Contractual term (in years)	8 years	6 years
Total intrinsic value of options exercised	$ 83	$ 136	$ 84
Performance Shares | Incentive Stock Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Vesting period (in years)	3 years
Unrecognized compensation expense	$ 26
Time-Vested Stock | Incentive Stock Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Vesting period (in years)	3 years
Unrecognized compensation expense	$ 56
Number of shares available for grant (in shares) | shares	10,990,000	0	0
Unrecognized compensation expense, weighted-average period of recognition in years	2 years
Total fair value of shares vested	$ 47	$ 58	$ 53
Program 2018
Stock Repurchases [Abstract]
Stock repurchase program, authorized amount				$ 5,000
Repurchased stock	$ 1,320

Capital Stock and Stock-Based_4

Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Common Stock Outstanding
Common stock balance, January 1 (in shares)	849,893,601	854,701,779	862,912,792
Common stock acquired (in shares)	16,518,163	18,701,843	17,219,642
Shares issued for stock options (in shares)	6,357,793	13,018,354	8,145,777
Shares issued for restricted stock and other (in shares)	747,053	875,311	862,852
Common stock balance, December 31 (in shares)	840,480,284	849,893,601	854,701,779
Treasury Stock
Treasury stock balance, January 1 (in shares)	615,812,759	611,004,581	602,793,568
Common stock acquired (in shares)	16,518,163	18,701,843	17,219,642
Shares issued for stock options (in shares)	6,357,793	13,018,354	8,145,777
Shares issued for restricted stock and other (in shares)	747,053	875,311	862,852
Treasury stock balance, December 31 (in shares)	625,226,076	615,812,759	611,004,581

Capital Stock and Stock-Based_5

Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Expected term of options	6 years	6 years	6 years
Expected volatility rate	20.30%	21.80%	19.20%
Risk-free interest rate	1.00%	0.50%	1.50%
Expected dividend yield	2.30%	2.30%	2.30%

Capital Stock and Stock-Based_6

Capital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity (Details) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Shares (in thousands)
Restricted stock awards - beginning balance (in shares) | shares	860
Granted (in shares) | shares	355
Forfeited (in shares) | shares	(189)
Restricted stock awards - ending balance (in shares) | shares	1,026
Weighted Average Grant Date Fair Value Per Award
Restricted stock awards - beginning of period (in dollars per share) | $ / shares	$ 73
Restricted stock awards - shares granted (in dollars per share) | $ / shares	70
Restricted stock awards - shares forfeited (in dollars per share) | $ / shares	81
Restricted stock awards - end of period (in dollars per share) | $ / shares	$ 70

Capital Stock and Stock-Based_7

Capital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity (Details) - Time-Vested Stock shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Shares (in thousands)
Restricted stock awards - beginning balance (in shares) | shares	1,897
Granted (in shares) | shares	749
Vested (in shares) | shares	(674)
Forfeited (in shares) | shares	(56)
Restricted stock awards - ending balance (in shares) | shares	1,916
Weighted Average Grant Date Fair Value Per Award
Restricted stock awards - beginning of period (in dollars per share) | $ / shares	$ 73
Restricted stock awards - shares granted (in dollars per share) | $ / shares	78
Weighted average grant date fair value of restricted stock awards - shares vested (in dollars per share) | $ / shares	70
Restricted stock awards - shares forfeited (in dollars per share) | $ / shares	74
Restricted stock awards - end of period (in dollars per share) | $ / shares	$ 76

Capital Stock and Stock-Based_8

Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Shares (in thousands)
Options - beginning balance (in shares) | shares	27,530
Granted (in shares) | shares	5,120
Exercised (in shares) | shares	(6,358)
Forfeited (in shares) | shares	(173)
Expired (in share) | shares	(24)
Options - ending balance (in shares) | shares	26,095
Options exercisable (in shares) | shares	16,725
Weighted Average Exercise Price
Options - beginning of period (in dollars per share) | $ / shares	$ 71
Options - shares granted (in dollars per share) | $ / shares	77
Options - shares exercised (in dollars per share) | $ / shares	68
Options - shares forfeited (in dollars per share) | $ / shares	75
Options - shares expired (in dollars per share) | $ / shares	73
Options - end of period (in dollars per share) | $ / shares	72
Options exercisable - end of period (in dollars per share) | $ / shares	$ 72
Weighted average remaining contractual life, options outstanding (in years)	5 years
Weighted average remaining contractual life, options exercisable (in years)	3 years
Intrinsic value of unexercised in-the-money options, options outstanding | $	$ 309
Intrinsic value of unexercised in-the-money options, options exercisable | $	$ 223

Employee Stock Ownership Plan (

Employee Stock Ownership Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Shares in ESOP (in shares)	10,290,667	11,545,950
Outstanding borrowings in the ESOP	$ 1
Common shares released and allocated to participant accounts (in shares)	9,559,255
Common shares available for future allocation to participant accounts (in shares)	731,412
Annual ESOP expense	$ 0	$ 0	$ 0
Dividends paid by the Company on shares held by the ESOP	20	23	25
Company contributions to the ESOP	$ 0	$ 0	$ 0

Retirement Plans and Other Re_3

Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation (Details)	Dec. 31, 2021
United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	100.00%
International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	100.00%
Equity securities | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	21.00%
Equity securities | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	22.00%
Fixed income securities | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	76.00%
Fixed income securities | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	63.00%
Real estate and other investments | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	3.00%
Real estate and other investments | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	15.00%

Retirement Plans and Other Re_4

Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input, by Major Asset Category (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Percent of fixed income assets invested in US treasury or agency securities	40.00%	50.00%
Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 0
Other Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	3	$ 37
Other Retiree Benefit Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	2
Other Retiree Benefit Plans | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1
Other Retiree Benefit Plans | Cash and cash equivalents | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | U.S. common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | International common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Pooled funds | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Fixed income securities | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	2
Other Retiree Benefit Plans | Guaranteed investment contracts | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Domestic, developed and emerging markets equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1
Other Retiree Benefit Plans | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Hedge funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Multi-Asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Retiree Benefit Plans | Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,834	1,921	1,806
United States | Pension Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	992	1,233
United States | Pension Plans | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	856	703
United States | Pension Plans | Cash and cash equivalents | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	38	50
United States | Pension Plans | U.S. common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | International common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Pooled funds | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	48	65
United States | Pension Plans | Fixed income securities | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	905	1,117
United States | Pension Plans | Guaranteed investment contracts | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	1
United States | Pension Plans | Domestic, developed and emerging markets equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	361	456
United States | Pension Plans | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	469	136
United States | Pension Plans | Hedge funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Multi-Asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26	77
United States | Pension Plans | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	34
United States | Pension Plans | Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(14)	(15)
International | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	723	698	$ 586
International | Pension Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	258	252
International | Pension Plans | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	465	446
International | Pension Plans | Cash and cash equivalents | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	12
International | Pension Plans | U.S. common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	1
International | Pension Plans | International common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	8
International | Pension Plans | Pooled funds | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	116	117
International | Pension Plans | Fixed income securities | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	67	59
International | Pension Plans | Guaranteed investment contracts | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	51	55
International | Pension Plans | Domestic, developed and emerging markets equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	97	183
International | Pension Plans | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	328	225
International | Pension Plans | Hedge funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	6
International | Pension Plans | Multi-Asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	2
International | Pension Plans | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	30
International | Pension Plans | Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Retirement Plans and Other Re_5

Retirement Plans and Other Retiree Benefits - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Expected benefit payments from company assets	$ 89
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Expected long-term rate of return on plan assets	5.70%
Pension Plans | United States
Defined Benefit Plan Disclosure [Line Items]
Percentage of investments in Company's common stock	0.00%
U.S. plans assets sold to Company (in shares)		739,869
U.S. plans assets purchased to Company (in shares)	0	0
Defined Benefit Plan Dividends Received On Employer Securities	$ 0	$ 0
Expected long-term rate of return on plan assets	5.70%	5.70%
Average annual rates of return for the most recent 1-year period	3.00%
Average annual rates of return for the most recent 5-year period	8.00%
Average annual rates of return for the most recent 10-year period	8.00%
Average annual rates of return for the most recent 15-year period	6.00%
Average annual rates of return for the most recent 25-year period	7.00%
Voluntary contributions to postretirement plans	$ 0	$ 0	$ 113
Other postretirement charges	$ (3)	$ 4	7
Pension Plans | International
Defined Benefit Plan Disclosure [Line Items]
Expected long-term rate of return on plan assets	2.72%	2.93%
Other postretirement charges	$ 1	$ 0	1
Other Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Expected long-term rate of return on plan assets		5.70%
Medical cost trend rate assumed for next fiscal year	6.00%
Ultimate medical cost trend rate	4.75%
Year which ultimate medical cost trend rate is reached	2026
Other postretirement charges	$ 0	$ 0	$ 0

Retirement Plans and Other Re_6

Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amounts Recognized in Balance Sheet
Current liabilities	$ (87)	$ (89)
Pension Plans
Weighted-Average Assumptions Used to Determine Benefit Obligations
Expected long-term rate of return on plan assets	5.70%
Other Retiree Benefit Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	$ 1,112	1,050
Service cost	26	20	$ 15
Interest cost	35	37	41
Participants’ contributions	0	0
Acquisitions/plan amendments	0	0
Actuarial loss (gain)	(50)	61
Foreign exchange impact	(8)	(9)
Termination benefits	0	0
Curtailments and settlements	0	0
Benefit payments	(35)	(47)
Other	0	0
Benefit obligations at end of year	1,080	1,112	1,050
Change in Plan Assets
Fair value of plan assets at beginning of year	3	37
Actual return on plan assets	0	2
Company contributions	32	11
Participants’ contributions	0	0
Foreign exchange impact	0	0
Settlements and acquisitions	0	0
Benefit payments	(35)	(47)
Other	0	0
Fair value of plan assets at end of year	0	3	37
Funded Status
Benefit obligations at end of year	1,080	1,112	1,050
Fair value of plan assets at end of year	0	3	37
Net amount recognized	(1,080)	(1,109)
Amounts Recognized in Balance Sheet
Noncurrent assets	0	0
Current liabilities	(47)	(45)
Noncurrent liabilities	(1,033)	(1,064)
Net amount recognized	(1,080)	(1,109)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	356	429
Transition/prior service cost	0	0
Amounts recognized in accumulated other comprehensive income	356	429
Accumulated benefit obligation	$ 0	$ 0
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	3.06%	2.88%
Expected long-term rate of return on plan assets		5.70%
Long-term rate of compensation increase	3.50%	3.50%
ESOP growth rate	6.00%	10.00%
Medical cost trend rate of increase	6.00%	6.00%
Interest Crediting Rate	0.00%	0.00%
United States | Pension Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	$ 2,363	$ 2,272
Service cost	0	1	1
Interest cost	61	74	90
Participants’ contributions	0	0
Acquisitions/plan amendments	(2)	0
Actuarial loss (gain)	(52)	171
Foreign exchange impact	0	0
Termination benefits	0	3
Curtailments and settlements	(5)	(3)
Benefit payments	(158)	(155)
Other	0	0
Benefit obligations at end of year	2,207	2,363	2,272
Change in Plan Assets
Fair value of plan assets at beginning of year	1,921	1,806
Actual return on plan assets	46	243
Company contributions	28	30
Participants’ contributions	0	0
Foreign exchange impact	0	0
Settlements and acquisitions	(3)	(3)
Benefit payments	(158)	(155)
Other	0	0
Fair value of plan assets at end of year	1,834	1,921	1,806
Funded Status
Benefit obligations at end of year	2,207	2,363	2,272
Fair value of plan assets at end of year	1,834	1,921	1,806
Net amount recognized	(373)	(442)
Amounts Recognized in Balance Sheet
Noncurrent assets	70	20
Current liabilities	(27)	(30)
Noncurrent liabilities	(416)	(432)
Net amount recognized	(373)	(442)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	866	902
Transition/prior service cost	0	1
Amounts recognized in accumulated other comprehensive income	866	903
Accumulated benefit obligation	$ 2,171	$ 2,325
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	2.98%	2.65%
Expected long-term rate of return on plan assets	5.70%	5.70%
Long-term rate of compensation increase	3.50%	3.50%
ESOP growth rate	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%
Interest Crediting Rate	2.85%	2.48%
International | Pension Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	$ 1,013	$ 876
Service cost	19	17	14
Interest cost	20	21	22
Participants’ contributions	6	5
Acquisitions/plan amendments	0	30
Actuarial loss (gain)	(39)	65
Foreign exchange impact	(38)	46
Termination benefits	0	0
Curtailments and settlements	(4)	(7)
Benefit payments	(40)	(40)
Other	0	0
Benefit obligations at end of year	937	1,013	876
Change in Plan Assets
Fair value of plan assets at beginning of year	698	586
Actual return on plan assets	45	59
Company contributions	33	36
Participants’ contributions	6	5
Foreign exchange impact	(14)	26
Settlements and acquisitions	(5)	26
Benefit payments	(40)	(40)
Other	0	0
Fair value of plan assets at end of year	723	698	586
Funded Status
Benefit obligations at end of year	937	1,013	876
Fair value of plan assets at end of year	723	698	$ 586
Net amount recognized	(214)	(315)
Amounts Recognized in Balance Sheet
Noncurrent assets	72	18
Current liabilities	(13)	(14)
Noncurrent liabilities	(273)	(319)
Net amount recognized	(214)	(315)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	179	255
Transition/prior service cost	9	7
Amounts recognized in accumulated other comprehensive income	188	262
Accumulated benefit obligation	$ 872	$ 946
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	2.10%	1.61%
Expected long-term rate of return on plan assets	2.72%	2.93%
Long-term rate of compensation increase	2.89%	2.62%
ESOP growth rate	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%
Interest Crediting Rate	0.84%	0.83%

Retirement Plans and Other Re_7

Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets (Details) - Pension Plans - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 805	$ 1,092
Fair value of plan assets	82	299
Accumulated benefit obligation	771	882
Fair value of plan assets	$ 81	$ 134

Retirement Plans and Other Re_8

Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans (Details) - Other Retiree Benefit Plans - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 1,080	$ 1,112
Fair value of plan assets	$ 0	$ 3

Retirement Plans and Other Re_9

Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Retiree Benefit Plans
Components of Net Periodic Benefit Cost
Service cost	$ 26	$ 20	$ 15
Interest cost	35	37	41
Expected return on plan assets	0	(2)	(3)
Amortization of transition and prior service costs (credits)	0	0	0
Amortization of actuarial loss	23	18	11
Net periodic benefit cost	84	73	64
Other postretirement charges	0	0	0
Total pension cost	$ 84	$ 73	$ 64
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate	2.88%	3.56%	4.43%
Expected long-term rate of return on plan assets	5.70%	6.30%	6.60%
Long-term rate of compensation increase	0.00%	0.00%	0.00%
ESOP growth rate	10.00%	10.00%	10.00%
Medical cost trend rate of increase	6.00%	6.00%	6.00%
Interest Crediting Rate	0.00%	0.00%	0.00%
United States | Pension Plans
Components of Net Periodic Benefit Cost
Service cost	$ 0	$ 1	$ 1
Interest cost	61	74	90
Expected return on plan assets	(106)	(111)	(103)
Amortization of transition and prior service costs (credits)	0	0	0
Amortization of actuarial loss	47	46	51
Net periodic benefit cost	2	10	39
Other postretirement charges	(3)	4	7
Total pension cost	$ (1)	$ 14	$ 46
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate	2.65%	3.40%	4.38%
Expected long-term rate of return on plan assets	5.70%	6.30%	6.60%
Long-term rate of compensation increase	3.50%	3.50%	3.50%
ESOP growth rate	0.00%	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%	0.00%
Interest Crediting Rate	2.48%	3.21%	4.26%
International | Pension Plans
Components of Net Periodic Benefit Cost
Service cost	$ 19	$ 17	$ 14
Interest cost	20	21	22
Expected return on plan assets	(20)	(22)	(19)
Amortization of transition and prior service costs (credits)	1	0	1
Amortization of actuarial loss	11	9	9
Net periodic benefit cost	31	25	27
Other postretirement charges	1	0	1
Total pension cost	$ 32	$ 25	$ 28
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate	1.61%	2.06%	2.80%
Expected long-term rate of return on plan assets	2.93%	3.38%	4.06%
Long-term rate of compensation increase	2.62%	2.83%	2.86%
ESOP growth rate	0.00%	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%	0.00%
Interest Crediting Rate	0.83%	0.85%	0.85%

Retirement Plans and Other R_10

Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments (Details) $ in Millions	Dec. 31, 2021USD ($)
Total benefit payments [Abstract]
2022	$ 237
2023	234
2024	241
2025	238
2026	244
2027-2031	1,205
Other Retiree Benefit Plans
Total benefit payments [Abstract]
2022	47
2023	48
2024	49
2025	50
2026	51
2027-2031	267
United States | Pension Plans
Total benefit payments [Abstract]
2022	147
2023	146
2024	147
2025	144
2026	147
2027-2031	692
International | Pension Plans
Total benefit payments [Abstract]
2022	43
2023	40
2024	45
2025	44
2026	46
2027-2031	$ 246

Income Taxes - Components of In

Income Taxes - Components of Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States	$ 1,256	$ 1,317	$ 1,050
International	1,831	2,330	2,251
Income before income taxes	$ 3,087	$ 3,647	$ 3,301

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States	$ 228	$ 259	$ 180
International	521	528	594
Total Provision for income taxes	$ 749	$ 787	$ 774

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Goodwill and intangible assets	$ 50	$ 1	$ 34
Property, plant and equipment	(19)	12	12
Pension and other retiree benefits	(4)	10	(13)
Stock-based compensation	11	(7)	(1)
Right-of-use assets/lease liabilities	(2)	(1)	0
Tax credits and tax loss carryforwards	(2)	(1)	3
Deferred withholding tax	(16)	111	(21)
Other, net	19	18	(33)
Total deferred tax benefit (provision)	$ 37	$ 143	$ (19)

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax at United States statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	1.10%	1.00%	0.60%
Earnings taxed at other than United States statutory rate	2.70%	3.30%	4.60%
Benefit for foreign tax matters	0.00%	(2.00%)	(0.90%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent	2.20%	0.00%	0.00%
Foreign-derived intangible income benefit	(2.20%)	(1.60%)	(1.30%)
Other, net	(0.50%)	(0.10%)	(0.60%)
Effective tax rate	24.30%	21.60%	23.40%
Provisional income tax benefit		$ 71,000,000
Foreign withholding income tax	$ 45,000,000	45,000,000
Valuation allowance against deferred tax asset		$ 26,000,000
Withholding tax due	$ 0
Income tax benefit related to changes in swiss preferential tax regime and increase to cantonal tax rate			$ 29,000,000

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred tax liabilities:
Goodwill and intangible assets	$ (523)	$ (603)
Property, plant and equipment	(301)	(281)
Right-of-use assets	(125)	(131)
Deferred withholding tax	(111)	(95)
Other	(35)	(52)
Total deferred tax liabilities	(1,095)	(1,162)
Deferred tax assets:
Pension and other retiree benefits	344	404
Tax credits and tax loss carryforwards	152	127
Lease liabilities	138	144
Accrued liabilities	234	250
Stock-based compensation	76	73
Other	69	125
Total deferred tax assets	1,013	1,123
Valuation Allowance	(120)	(96)
Net deferred tax assets	893	1,027
Net deferred income taxes	$ (202)	$ (135)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Income tax expense (benefit) allocated directly to equity	$ 146,000,000	$ (101,000,000)	$ (13,000,000)
Unrecognized tax benefits that would impact effective tax rate	235,000,000
Interest (income) expense recognized related to unrecognized tax benefits	10,000,000	9,000,000	0
Accrued interest related to unrecognized tax benefits	$ 35,000,000	$ 24,000,000	$ 23,000,000
Minimum
Income Taxes [Line Items]
Statue of limitations on foreign jurisdictions for tax audits	3 years
Maximum
Income Taxes [Line Items]
Statue of limitations on foreign jurisdictions for tax audits	6 years

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Unrecognized tax benefits:
Balance, January 1	$ 227	$ 173	$ 190
Increases as a result of tax positions taken during the current year	26	18	14
Decreases of tax positions taken during prior years	(20)	(5)	(21)
Increases of tax positions taken during prior years	40	57	20
Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations	(23)	(19)	(30)
Effect of foreign currency rate movements	(5)	3	0
Balance, December 31	$ 245	$ 227	$ 173

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net income attributable to Colgate-Palmolive Company
Basic EPS	$ 2,166	$ 2,695	$ 2,367
Diluted EPS	$ 2,166	$ 2,695	$ 2,367
Shares (millions)
Basic EPS (in shares)	845	856.8	859.1
Stock options and restricted stock units (in shares)	3.3	2.5	2
Diluted EPS (in shares)	848.3	859.3	861.1
Per Share
Basic EPS (in dollars per share)	$ 2.56	$ 3.15	$ 2.76
Diluted EPS (in dollars per share)	$ 2.55	$ 3.14	$ 2.75

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,495,393	3,257,310	19,901,202
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	126,378	25,381	4,516

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2019USD ($)	Dec. 31, 2021USD ($)casecountry_and_territory	Dec. 31, 2020case	Jul. 31, 2017USD ($)	Dec. 31, 2005USD ($)
Loss Contingencies [Line Items]
Contractual commitments, amount		$ 724
Number of countries in which entity operates | country_and_territory		200
Brazilian internal revenue authority, matter 1		$ 106
Loss contingency, number of cases on appeal | case		5
Brazilian internal revenue authority, matter 2					$ 47
Fine imposed by greek competition authority				$ 11
Increase (decrease) in fine imposed by Greek competition authority	$ 10.5
Loss contingency, pending claims, number (in cases) | case		171	136
Loss contingency, new claims filed, number (in cases) | case		74
Loss contingency, claims dismissed or settled, number (in cases) | case		39
Minimum
Loss Contingencies [Line Items]
Range of reasonably possible losses		$ 0
Maximum
Loss Contingencies [Line Items]
Range of reasonably possible losses		$ 425

Segment Information - Narrative

Segment Information - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)business_segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of product segments (in segments) | business_segment	2
Number of reportable segments (in segments) | business_segment	5
Number of operating segments (in segments) | business_segment	5
Goodwill and indefinite-lived intangible impairment charges	$ 571	$ 0	$ 0
Restructuring and related cost, incurred cost	0	(13)	57
Global Growth and Efficiency Program
Segment Reporting Information [Line Items]
Restructuring and related cost, incurred cost			132
Operating Profit | Corporate
Segment Reporting Information [Line Items]
Goodwill and indefinite-lived intangible impairment charges	571
Acquisition-related costs		6	24
Benefit from foreign tax matter	$ 26		30
Gross Profit | Global Growth and Efficiency Program
Segment Reporting Information [Line Items]
Restructuring and related cost, incurred cost		$ 16	$ 125
Sales Revenue, Net
Segment Reporting Information [Line Items]
Percentage of consolidated Net sales represented by sales outside US	70.00%
Percentage of consolidated Net sales coming from emerging markets	45.00%
Sales Revenue, Net | Customer Concentration Risk | Walmart, Inc.
Segment Reporting Information [Line Items]
Percentage of consolidated sales represented by one customer	12.00%	12.00%	11.00%

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 17,421	$ 16,471	$ 15,693
Operating profit	3,332	3,885	3,554
Capital expenditures	567	409	335
Depreciation and amortization	556	539	519
Identifiable assets	$ 15,040	$ 15,920	$ 15,034
Percentage of corporate identifiable assets consisting of investments in equity securities	87.00%	95.00%	92.00%
Percentage of corporate identifiable assets consisting of derivative instruments	10.00%		2.00%
Total long lived assets	$ 4,256	$ 4,237	$ 4,254
United States
Segment Reporting Information [Line Items]
Total long lived assets	1,981	1,889	1,895
Non-US
Segment Reporting Information [Line Items]
Total long lived assets	2,275	2,348	2,359
Oral, Personal and Home Care | United States
Segment Reporting Information [Line Items]
Net sales	3,391	3,447	3,166
Pet Nutrition | United States
Segment Reporting Information [Line Items]
Net sales	2,018	1,712	1,441
Operating Segments | Oral, Personal and Home Care
Segment Reporting Information [Line Items]
Net sales	14,110	13,588	13,168
Operating profit	3,495	3,594	3,505
Capital expenditures	332	274	223
Depreciation and amortization	395	380	358
Identifiable assets	13,619	14,646	13,809
Operating Segments | Oral, Personal and Home Care | North America
Segment Reporting Information [Line Items]
Net sales	3,694	3,741	3,424
Operating profit	754	988	982
Capital expenditures	87	65	43
Depreciation and amortization	104	101	94
Identifiable assets	4,058	4,132	3,576
Operating Segments | Oral, Personal and Home Care | Latin America
Segment Reporting Information [Line Items]
Net sales	3,663	3,418	3,606
Operating profit	1,012	975	963
Capital expenditures	118	104	90
Depreciation and amortization	88	81	84
Identifiable assets	2,369	2,251	2,384
Operating Segments | Oral, Personal and Home Care | Europe
Segment Reporting Information [Line Items]
Net sales	2,841	2,747	2,450
Operating profit	682	652	624
Capital expenditures	44	41	42
Depreciation and amortization	98	94	72
Identifiable assets	4,432	5,386	5,104
Operating Segments | Oral, Personal and Home Care | Asia Pacific
Segment Reporting Information [Line Items]
Net sales	2,867	2,701	2,707
Operating profit	844	773	749
Capital expenditures	50	51	40
Depreciation and amortization	96	95	100
Identifiable assets	2,161	2,272	2,155
Operating Segments | Oral, Personal and Home Care | Africa/Eurasia
Segment Reporting Information [Line Items]
Net sales	1,045	981	981
Operating profit	203	206	187
Capital expenditures	33	13	8
Depreciation and amortization	9	9	8
Identifiable assets	599	605	590
Operating Segments | Pet Nutrition
Segment Reporting Information [Line Items]
Net sales	3,311	2,883	2,525
Operating profit	901	793	703
Capital expenditures	147	56	41
Depreciation and amortization	62	58	55
Identifiable assets	1,342	1,210	1,175
Corporate
Segment Reporting Information [Line Items]
Operating profit	(1,064)	(502)	(654)
Capital expenditures	88	79	71
Depreciation and amortization	99	101	106
Identifiable assets	$ 79	$ 64	$ 50

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease, payments	$ 173	$ 193
Right-of-use asset obtained in exchange for operating lease liability	$ 197	$ 163
Operating lease, weighted average remaining lease term	8 years	8 years
Operating lease, weighted average discount rate	4.00%	4.20%

Leases - Balance Sheet (Details

Leases - Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Other assets	$ 527	$ 521
Other accruals	137	137
Other liabilities	451	476
Total operating lease liabilities	$ 588	$ 613
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accruals	Other accruals
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other liabilities	Other liabilities

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Commitments (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 156
2023	109
2024	76
2025	61
2026	48
Thereafter	235
Total lease commitments	685
Less: Interest	(97)
Present value of lease liabilities	$ 588	$ 613

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 142	$ 155
Short-term lease cost	7	3
Variable lease cost	20	20
Sublease Income	(1)	0
Total lease cost	$ 168	$ 178

Supplemental Income Statement_3

Supplemental Income Statement Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other (income) expense, net
Global Growth and Efficiency Program	$ 0	$ (13)	$ 57
Amortization of intangible assets	89	88	62
Equity income	(12)	(12)	(9)
Value-added tax matter in Brazil	(26)	0	(30)
Write-off of certain investments and fixed assets	10	0	51
Acquisition-related costs	0	2	21
Charges for a change in go-to-market strategy in certain countries	0	0	15
Other, net	4	48	29
Total Other (income) expense, net	65	113	196
Interest (income) expense, net
Interest incurred	195	184	193
Interest capitalized	(3)	(1)	(1)
Interest income	(17)	(19)	(47)
Total Interest (income) expense, net	175	164	145
Research and development	307	290	281
Advertising	$ 2,021	$ 1,948	$ 1,694

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventories
Raw materials and supplies	$ 505	$ 454
Work-in-process	39	45
Finished goods	1,248	1,256
Total Inventories, net	1,792	1,755
Non-current inventory, net	(100)	(82)
Current Inventories, net	$ 1,692	$ 1,673

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Inventories valued under LIFO	$ 410	$ 439
Excess of current cost over LIFO cost	$ 60	$ 65

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, plant and equipment, net
Land	$ 163	$ 166
Buildings	1,603	1,623
Manufacturing machinery and equipment	5,527	5,409
Other equipment	1,606	1,553
Property, plant and equipment, gross	8,899	8,751
Accumulated depreciation	(5,169)	(5,035)
Property, plant and equipment, net	$ 3,730	$ 3,716

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Schedule of Other Accruals (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other accruals
Accrued advertising and coupon redemption	$ 709	$ 728
Accrued payroll and employee benefits	353	401
Accrued taxes other than income taxes	118	116
Restructuring accrual	7	21
Pension and other retiree benefits	87	89
Lease liabilities due in one year	137	137
Accrued interest	38	39
Derivatives	6	93
Other	630	717
Other accruals	$ 2,085	$ 2,341

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information - Schedule of Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other liabilities
Pension and other retiree benefits	$ 1,722	$ 1,815
Restructuring accrual	2	10
Long-term lease liabilities	451	476
Other	254	354
Total Other liabilities	$ 2,429	$ 2,655

Supplemental Other Comprehens_3

Supplemental Other Comprehensive Income (Loss) Information - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total Other comprehensive income (loss), net of tax	$ (43)	$ (66)	$ (87)
Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), Pretax	(99)	(119)	49
Total Other comprehensive income (loss), net of tax	(191)	(30)	27
Pension and other benefits
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), before reclassifications, Pretax	102	(125)	(204)
Reclassification from AOCI, Pretax	82	74	72
Other comprehensive income (loss), Pretax	184	(51)	(132)
Other comprehensive income (loss), before reclassifications, Net of Tax	71	(97)	(154)
Reclassification from AOCI, Net of Tax	63	57	54
Total Other comprehensive income (loss), net of tax	134	(40)	(100)
Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), before reclassifications, Pretax	13	(3)	(9)
Reclassification from AOCI, Pretax	7	0	(6)
Other comprehensive income (loss), Pretax	20	(3)	(15)
Other comprehensive income (loss), before reclassifications, Net of Tax	10	(2)	(7)
Reclassification from AOCI, Net of Tax	6	0	(5)
Total Other comprehensive income (loss), net of tax	16	(2)	(12)
Accumulated Other Comprehensive Income (Loss)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), Pretax	105	(173)	(98)
Total Other comprehensive income (loss), net of tax	$ (41)	$ (72)	$ (85)

Supplemental Other Comprehens_4

Supplemental Other Comprehensive Income (Loss) Information - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Unrecognized pension and other retiree benefit costs, aftertax	$ 1,044	$ 1,178
Foreign currency translation adjustments	$ 3,349	$ 3,158

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts and estimated returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance of valuation allowance and reserves	$ 89	$ 76	$ 82
Charged to Costs and Expenses, additions	35	16	6
Other, additions	0	0	0
Deductions	46	3	12
Ending balance of valuation allowance and reserves	78	89	76
Valuation allowance for deferred tax assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance of valuation allowance and reserves	96	115	54
Charged to Costs and Expenses, additions	27	31	68
Other, additions	0	0	0
Deductions	3	50	7
Ending balance of valuation allowance and reserves	$ 120	$ 96	$ 115